



Cite this: *Org. Biomol. Chem.*, 2021, **19**, 5312

Synthesis, structure and midkine binding of chondroitin sulfate oligosaccharide analogues†

Myriam Torres-Rico,  Susana Maza, José L. de Paz * and Pedro M. Nieto *

The preparation of chondroitin sulfate (CS) oligosaccharide mimetics, more easily synthesized than natural sequences, is a highly interesting task because these compounds pave the way for modulation of the biological processes in which CS is involved. Herein, we report the synthesis of CS type E analogues which present easily accessible glucose units instead of glucuronic acid (GlcA) moieties. NMR experiments and molecular dynamics simulations showed that the 3D structure of these compounds is similar to the structure of the natural CS-E oligosaccharides. In addition, fluorescence polarization (FP) and saturation transfer difference NMR (STD-NMR) experiments revealed that the synthesized CS-like derivatives were able to interact with midkine, a model heparin-binding growth factor, suggesting that the presence of the GlcA carboxylate groups is not essential for the binding. Overall, our results indicate that the synthesized glucose-containing oligosaccharides can be considered as functional and structural CS mimetics.

Received 5th May 2021,
Accepted 25th May 2021

DOI: 10.1039/d1ob00882j

rsc.li/obc

Introduction

Chondroitin sulfate (CS) is a structurally heterogeneous polysaccharide belonging to the glycosaminoglycan (GAG) family that participates in a wide range of biological processes.¹ Chondroitin sulfate E (CS-E) is a particular type of this polysaccharide, characterized by the disulfated disaccharide unit GalNAc(4,6-di-OSO₃)-β(1 → 4)-GlcA-β(1 → 3). Although CS-E sequences constitute a minor part of naturally existing CS, this sulfation motif plays a relevant role in central nervous system development, growth factor signaling and pathogen attachment.² For example, it has been demonstrated that CS-E tetrasaccharides specifically recognize certain proteins, modulating neuronal growth.^{3,4} One of these proteins is midkine, a heparin binding growth factor that is also involved in cancer and inflammation.^{5,6}

Structurally defined CS oligosaccharides are required to establish structure–activity relationships and study CS-protein interactions at the molecular level. Thus, several research groups have reported the chemical synthesis of CS oligomers,^{7,8} including CS-E domains.^{9–14} However, despite recent impressive advances,¹⁵ the preparation of CS sequences is still a complicated task. The synthesis of well-defined CS analogues, which mimic the natural CS sequences and are more easily synthesized, is an attractive alternative. Reported

CS/GAG mimetics¹⁶ include multivalent systems,^{17–20} sulfated carbohydrate derivatives^{21–26} and non-carbohydrate sulfated compounds.^{27–29} These mimetics could potentially modulate the CS-protein interactions that are responsible for critical biological processes. In this context, Mallet and coworkers published in 2013 the synthesis of CS-E oligosaccharide analogues where the galactosamine units were replaced by galactose building blocks.³⁰ This modification facilitated the access to these compounds because lactose was employed as starting material, avoiding the use of expensive galactosamine moieties. *In vitro* and *in vivo* biological experiments demonstrated the ability of these analogues to mimic natural CS-E.

Inspired by this, we report here the preparation of a novel type of CS-E oligosaccharide mimetics containing glucose instead of glucuronic acid (GlcA). In particular, the synthesis of tetrasaccharide **1** and pentasaccharide **2** is described (Fig. 1). The synthetic access to natural CS-E sequences is ham-




Fig. 1 Structures of CS oligosaccharide mimetics **1** and **2**. Pyranose rings labelling with letters A–D (or A–E) is employed throughout the text. MP = 4-methoxyphenyl.

Glycosystems Laboratory, Instituto de Investigaciones Químicas (IIQ), cicCartuja, CSIC and Universidad de Sevilla, Americo Vespucio, 49, 41092 Sevilla, Spain.

E-mail: pedro.nieto@iiq.csic.es, jlpaz@iiq.csic.es

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1ob00882j



pered by the use of GlcA units that are considered as disarmed building blocks due to the presence of the electron-withdrawing carboxylic acid at position 5. Thus, glycosyl donors derived from GlcA are often associated with low-yielding glycosylation reactions.^{31,32} We envisioned that the replacement of GlcA by easily accessible glucose units would facilitate the synthesis of CS-E like oligosaccharides. In this manuscript, we also study the 3D structure of the synthesized analogues by NMR and molecular dynamics (MD) simulations. Moreover, the interaction between these compounds and midkine was analyzed by fluorescence polarization (FP) and saturation transfer difference NMR (STD-NMR) experiments. The preparation of derivatives such as **1** and **2** enabled us to study the importance of carboxylic acid functions in the interactions between CS and midkine by comparison with the natural GlcA containing oligomers.

Results and discussion


Synthesis of CS mimetics

For the synthesis of these CS mimetics, we employed known monosaccharide building blocks **7**¹⁴ and **8**³³ as starting materials (Scheme 1), easily prepared from D-galactosamine hydrochloride and 1,2,5,6-di-O-isopropylidene- α -D-glucopyranose, respectively. Disaccharide **9** was obtained in high yield (82%) by glycosylation between **8** and trichloroacetimidate donor **7**. 1,2-*trans* Glycosidic linkage was exclusively formed due to the presence of the *N*-trifluoroacetyl (*N*-TFA) participating group. Disaccharide **9** was then transformed into adequate donor and acceptor to prepare the tetrasaccharide derivative by 2 + 2 coupling. Acetate groups were selectively removed by using *p*-toluenesulfonic acid in a CH₂Cl₂/MeOH mixture. Introduction of the silylene group on triol **10** using di-*tert*-butylsilyl bis(trifluoromethanesulfonate) (*t*Bu₂Si(OTf)₂) in pyridine afforded disaccharide acceptor **11** in 94% yield. The presence of this orthogonal silylene protecting group at positions 4 and 6 of the galactosamine units allowed the selective sulfation of these positions at the end of the synthetic route to


generate CS-E related sequences. Levulinoylation of the remaining 3-OH followed by oxidative removal of the 4-methoxyphenyl group using ceric ammonium nitrate (CAN) provided the 1-hydroxy sugar **12**. Trichloroacetimidate **13** was prepared in high yield by treatment with trichloroacetonitrile and K₂CO₃.

With donor and acceptor disaccharides in hand, we studied the 2 + 2 coupling to yield tetrasaccharide **14** (Scheme 2). Building block **11** was first reacted with 1.5 equiv. of donor **13** under trimethylsilyl trifluoromethanesulfonate (TMSOTf) catalysis at 0 °C. The corresponding tetramer **14** was obtained in only 22% yield. ¹⁹F NMR spectrum showed two singlets at $\delta = -75.6$ and -75.7 ppm corresponding to the two trifluoroacetyl moieties. When this glycosylation was performed at room temperature with 2.5 equiv. of donor, using TMSOTf as the promoter, tetrasaccharide **14** was isolated in 44% yield. A similar result (47%) was obtained by using 3 equiv. of donor **13** and *tert*-butyldimethylsilyl trifluoromethanesulfonate (TBSOTf) activation at room temperature (Scheme 2). Therefore, an excess of glycosyl donor (2.5–3 equiv.) at room temperature was required to produce tetrasaccharide **14** in an acceptable yield due to the low reactivity shown by disaccharide **11**. A similar glycosylation outcome was previously obtained by us when using the equivalent GlcA disaccharide building blocks.¹⁴

Next, silylene groups were selectively removed by treatment with an excess of (HF)_{*n*}Py complex in THF at 0 °C (Scheme 2). Microwave-assisted sulfation³⁴ using SO₃-Me₃N complex in DMF gave tetrasulfated derivative **5** as sodium salt after purification by size exclusion and silica gel chromatographies and treatment with Dowex-Na⁺ ion-exchange resin. ¹H and ¹³C NMR spectra showed the typical downfield shifts of the signals at sulfated positions. Basic hydrolysis of esters and trifluoroacetyl amides was carried out by treatment with H₂O₂/LiOH and NaOH. The released amino groups were then selectively acetylated to afford **3** in good yield after size exclusion chromato-



Scheme 1 Reagents and conditions: (a) TMSOTf, CH₂Cl₂, 0 °C, 82%; (b) *p*-toluenesulfonic acid, CH₂Cl₂/MeOH, 69%; (c) *t*Bu₂Si(OTf)₂, Py, 94%; (d) Lev₂O, DMAP, CH₂Cl₂; CAN, CH₂Cl₂/CH₃CN/H₂O, 88%; (e) Cl₃CCN, K₂CO₃, CH₂Cl₂, 94%. DMAP = 4-(dimethylamino)pyridine.




Scheme 2 Reagents and conditions: (a) TBSOTf, CH₂Cl₂, 47%; (b) (HF)_{*n*}Py, THF, 0 °C, 99%; (c) SO₃-Me₃N, DMF, 100 °C, microwave (MW) heating, 84%; (d) LiOH, H₂O₂, THF; NaOH, MeOH; Ac₂O, Et₃N, MeOH, 85%; (e) H₂, Pd(OH)₂/C, H₂O/MeOH, 98%.



graphy. Finally, the benzyl ethers were removed by hydrogenation over Pd(OH)₂/C to give fully deprotected compound **1**. The structure of **1** was confirmed by NMR and mass spectroscopic analysis.

For the preparation of CS related pentamer **2**, we first accomplished the synthesis of trisaccharide **17** by 2 + 1 coupling of trichloroacetimidate **13** and known monosaccharide acceptor **16**³⁵ (Scheme 3). Remarkably, this glycosylation proceeded better than the condensation between **13** and **11**, and the trisaccharide was isolated in 56% yield by employing only 1.5 equiv. of donor at room temperature under TMSOTf activation. Increasing the amount of **13** (up to 2.5 equiv.) did not lead to a better result. Treatment of **17** with hydrazine monohydrate gave trisaccharide **18**, ready for elongation at 3-OH. Glycosylation of **18** with trichloroacetimidate **13** at room temperature afforded pentasaccharide **19** (Table 1). When using 1.5 equiv. of donor, pentasaccharide was isolated in low yield (entries 1 and 2). Increasing the amount of activator (up to 60 mol% with respect to the donor)³⁶ did not improve the result (entry 3). Interestingly, silylene functionalities proved to be stable under these highly acidic reaction conditions. The

yield of **19** was finally raised to 52% (+24% of unreacted acceptor **18**) by using 3 equiv. of donor and TBSOTf activation at room temperature (entry 4). ¹H and ¹³C NMR spectra were assigned by using 2D experiments (COSY and HSQC). Three ¹⁹F NMR signals appeared at $\delta = -75.5, -75.8$ and -76.0 ppm for the trifluoroacetyl moieties. Cleavage of the silylene groups followed by extensive sulfation under microwave heating afforded hexasulfated, water soluble pentamer **6** (Scheme 3). The NMR chemical shifts of the H-4 and H-6 protons in galactosamine residues confirmed the presence of sulfate groups at these positions (Table 2). The 4,6-di-*O*-sulfation was also supported by the changes in the chemical shifts of C-4 and C-6 carbons in galactosamine units (Table 2). Hydrolysis of esters and amides involved treatment with H₂O₂/LiOH followed by aqueous NaOH. Although this two-step saponification procedure is typical for deprotection of uronic acid containing oligosaccharides, avoiding the β -elimination side reaction,³⁷ we also obtained a better yield using this method in comparison with the direct treatment with aqueous NaOH in MeOH. The three amino groups were then selectively acetylated with acetic anhydride and triethylamine in MeOH to afford dibenzylated **4** in excellent yield. Finally, hydrogenolysis of **4** gave the fully deprotected pentasaccharide **2**. The NMR and mass spectra were in good agreement with the structure.



Scheme 3 Reagents and conditions: (a) **13**, TMSOTf, CH₂Cl₂, 56% and unreacted **16** (26%); (b) NH₂NH₂·H₂O, Py/AcOH, CH₂Cl₂, 95%; (c) **13**, TBSOTf, CH₂Cl₂, 52% and unreacted **18** (24%); (d) (HF)_n·Py, THF, 0 °C, 97%; (e) SO₃·Me₃N, DMF, 100 °C, MW heating, 78%; (f) LiOH, H₂O₂, THF; NaOH, MeOH; Ac₂O, Et₃N, MeOH, 89%; (g) H₂, Pd(OH)₂/C, H₂O/MeOH, quantitative.

Fluorescence polarization (FP) experiments

With compounds **1** and **2** in hand, their interactions with midkine were analyzed in order to demonstrate that these derivatives are mimetics of the natural products. As mentioned before, midkine is a relevant protein target that binds heparin and CS-E. Sulfated intermediates **3–6** were also included in this study because we have previously demonstrated that compounds displaying hydrophobic functionalities strongly bind to midkine protein.³⁸ In order to calculate relative binding affinities and obtain IC₅₀ values, a FP competition experiment was used.^{33,35} As previously reported, the FP of samples containing a fixed amount of protein and fluorescent probe and

Table 2 ¹H and ¹³C NMR chemical shift ranges (in ppm) for galactosamine units of compounds **20** and **6** (before and after sulfation, respectively)

Compound	H-4	H-6	C-4	C-6
20	3.94–4.04	3.44–3.94	66.3–68.2	61.6–62.5
6	4.87–4.89	4.08–4.44	72.4–76.8	67.8–68.9

Table 1 Glycosylation reactions between trisaccharide **18** and disaccharide **13**

Entry	Donor 13 (equiv.)	Promotor/amount	Isolated yield 19 (%)	Recovered acceptor 18 (%)
1 ^a	1.5	TMSOTf, 20 mol% ^b	30	49
2 ^a	1.5	TBSOTf, 20 mol% ^b	34	40
3 ^a	1.5	TBSOTf, 60 mol% ^b	34	42
4 ^a	3	TBSOTf, 20 mol% ^b	52	24

^a The glycosylations were run in CH₂Cl₂ at room temperature. ^b mol% with respect to the donor.






Fig. 2 Representative inhibition curves showing the ability of compounds **1–6** to inhibit the interaction between midkine (63 nM) and fluorescent probe (10 nM). 100% residual midkine/fluorescent probe complex indicates 0% inhibition while 0% residual complex means 100% inhibition. In order to calculate the IC_{50} values, the curves were fitted to the equation for a one-site competition interaction model.

increasing concentrations of the different CS mimetics was measured (Fig. 2 and ESI†). The resulting inhibition curves were fitted and IC_{50} values, defined as the CS mimetic concentration required for 50% inhibition, were determined (Table 3 and ESI†). These binding affinities were compared with those previously obtained for CS-E tetrasaccharide derivatives bearing GlcA units (Fig. 3).³⁸ Fully deprotected tetra- and pentasaccharides **1** and **2** bound to midkine in the high micromolar range (IC_{50} = 189 and 130 μ M, respectively). Previously synthesized CS-E tetrasaccharide **21** showed a similar affinity (IC_{50} = 254 μ M, Fig. 3).³⁸ Therefore, our data indicated that glucose containing oligosaccharides **1–2** mimicked the natural CS-E sequences and were able to recognize midkine, with binding affinities in the same range. Regarding partially deprotected compounds **3** and **4** (Table 3), our results indicated that the presence of hydrophobic benzyl groups enhanced the binding to midkine giving valuable information for the design of high-affinity ligands (compare IC_{50} values of **1–2** and **3–4**). These results are in good agreement with previous reports pointing out interesting biological activities and protein binding properties of GAG mimetics containing hydrophobic scaffolds or groups.^{39–41} Thus, fully protected derivatives **5** and **6** showed a \approx 30–50 fold inhibition increase in comparison with the fully deprotected oligosaccharides **1** and **2** (Table 3). Importantly, these molecules were soluble in water at 100 μ M concentration (**5** in the presence of 1% of DMSO). These results suggest that compounds such as **3–6** can be useful for the modulation of




Fig. 3 Structure and IC_{50} value of CS-E tetrasaccharide derivative **21**.

CS-protein interactions and the subsequent biological activities.

Three-dimensional structure of CS mimetics by NMR and molecular dynamics (MD)

In order to determine the 3D structure of the compounds previously described, we decided to perform an NMR analysis.⁴² This study would allow us to compare the structure of the CS mimetics and the natural oligosaccharides, with particular emphasis in potential changes coming from the replacement of the carboxylate moieties by hydroxymethyl groups.

For this purpose, we recorded NMR spectra of the synthesized oligosaccharides in pure water. The $^3J_{HH}$ coupling constants for **1–4** were calculated (see Tables S1 and S3†) to analyse the ring conformations. On the other hand, we also obtained the interprotonic experimental distances for **1–4** (see Tables S2 and S4†) from NOESY experiments (Fig. 4 and S7†) at variable mixing times by using the initial rate approximation.⁴³ In particular, the interglycosidic NOE were analysed to estimate the interglycosidic distances and define the glyco-




Fig. 4 NOESY spectrum of tetrasaccharide **3** at 1.5 mM, 300 K and 600 MHz, in D_2O , mixing time 1000 ms.

Table 3 IC_{50} values for CS mimetics obtained in FP midkine competition assays

Compound	1	2	3	4	5	6
IC_{50}^a (μ M)	189 \pm 107	130 \pm 80	154 \pm 35	83 \pm 1	3.6 \pm 1.3	3.8 \pm 0.1

^aThe IC_{50} and the error represent the average and the standard deviation from at least two independent experiments.



sidic linkage geometry. Internal ring distances between non-consecutive protons were used to confirm the conformation estimated by $^3J_{\text{HH}}$.

In all the cases measured, the coupling constants were compatible with the $^4\text{C}_1$ conformation of the pyranose rings (see Tables S1 and S3†). We also confirmed the $^4\text{C}_1$ conformation by analysing the intra-ring H1–H3–H5 distances; in all cases they were compatible with the expected chair (see Tables S2 and S4†). Once evaluated the conformations of the individual sugar rings, we studied the interprotonic distances between both sides of the glycosidic linkages. The arrangement of all the glycosidic linkages can be detected by the observation of NOE between the anomeric proton and the proton *ipso* relative to the glycosidic linkage for *syn*- Ψ arrangements (H1–H4 distance for GalNAc β (1 \rightarrow 4)Glc linkages and H1–H3 for Glc β (1 \rightarrow 3)GalNAc bonds; for example, see Fig. 4: interglycosidic peaks H1D–H4C, H1C–H3B, H1B–H4A). In all the cases, they were compatible with a prevalence of the *syn*- Ψ rotamer while signs of the presence of the *anti*- Ψ conformer were absent beyond the limit of sensitivity (5%).

The NMR analysis of fully protected derivatives 5 and 6 in D_2O was severely hampered due to solubility problems (5) and signals overlapping and broadening (6). In any case, no evidences for different ring conformations or other glycosidic linkage arrangements were detected for 6.

Overall, the NMR results qualitatively agree with the observations for natural CS oligosaccharides.¹⁴ For deprotected oligosaccharides 1–2, and also for partially protected 3–4 and fully substituted 6, in spite of the large steric hindrance of the substituents, the arrangement of the glycosidic linkages and the sugar ring conformations were the same as in the CS case.¹⁴ Therefore, the replacement of GlcA units by glucose moieties, in spite of changing the charges balance of the oligosaccharide, does not have influence on the global three dimensional arrangement.

Next, MD simulations were carried out and the results were compared with the NMR experimental data. We calculated the MD trajectories using AMBER software with GLYCAM parameters for pyranoses (see experimental part for details). Tetrasaccharide 1 and pentasaccharide 2, the two compounds with no benzylic substituents in their backbone, yielded averaged 3D structures compatible with the experimental observations, $^3J_{\text{HH}}$ and NOEs (Tables S1–S4†). Their 3D shapes can be described as a high pitch helical structure, almost quasilinear, with four residues per turn, which is virtually a linear and elongated shape (Fig. 5). All the sugar rings have a monoconformational behavior being in $^4\text{C}_1$ conformation, and the glycosidic linkages are in a *syn*- Ψ disposition (see ESI† for puckering coordinates and Φ, Ψ trajectories). The introduction of an extra GalNAc residue at the reducing end in 2 does not influence the




Fig. 5 Three-dimensional structures for each oligosaccharide randomly taken from MD simulations. (A) Tetrasaccharide 1 (500 ns MD); (B) pentasaccharide 2 (500 ns MD); (C) tetrasaccharide 3 (8 ns MD-tar); (D) pentasaccharide 4 (50 ns MD-tar); (E) tetrasaccharide 5 (8 ns MD-tar); (F) pentasaccharide 6 (250 ns MD).



behaviour of the glycosidic linkages nor the ring pucker. This is in full agreement with the previous NMR analysis.

When we performed a similar study for **3** and **4**, we found theoretical results in disagreement with the experimental observations (Tables S1–S4†). The conformations of the glucose rings displaying benzyl groups at position 3, became incompatible with the experimental observations with frequent visits to the equator of the Cremer-Pople puckering sphere. Then, we decided to explore the time-averaged restrained MD (tar-MD) solution to solve this artefact by restraining the in-ring H1–H3–H5 distances to the experimental ones.⁴⁴ This strategy only should affect to the conformation of the corresponding ring, fixing the conformation without affecting any other structural issues. Then, we back-calculated the NMR magnitudes from the tar-MD structures and they showed an excellent agreement with the experimental observations (Tables S1–S4†). All the coupling constants were compatible with ⁴C₁ chair conformations of the sugar rings. Furthermore, the calculated interprotonic distances were also compatible with the experimental ones.

In particular, in the case of **3**, when we run a short tar-MD of 8 ns, the simulations became compatible with the experimental results with all the rings in ⁴C₁ conformation (Fig. 6, top). The introduction of these restrictions not only fixed the six membered ring conformations but also yielded a glycosidic linkages behavior compatible with the NOESY observations, that corresponds with a syn-Ψ geometry (Fig. 6, bottom). We do not have an explanation for this performance as the restriction at the ring are not directly related with the glycosidic linkage geometry. In addition, a reduction on the flexibility of the glycosidic linkages was observed. For **4**, the tar-MD needed more time (50 ns) to reach the agreement with the experimental data (see ESI†).

STD-NMR experiments

Finally, we performed an NMR analysis on the complexes between midkine and the synthesized CS mimetics.^{45–47} Thus, we recorded NOESY and STD-NMR experiments at different saturation times for **1–4** in the presence of 20 μM midkine. The reference experiments (in the absence of protein) were recorded in the same buffer (10 mM phosphate, 150 mM NaCl pH = 7.5) used to measure the interactions in order to guarantee the same motional behaviour with or without midkine, avoiding the potential effects in the NMR spectrum of the salt concentration. The signals of the sugar ligands in the complexes appear at the same chemical shift that they were assigned in the absence of the protein. The formation of the complex was confirmed by an appreciable broadening, sign of complex formation as the sign of the NOE effect cannot be used because it is already negative for the free compound.

All the compounds **1–4** gave STD signals compatible with the binding to midkine (see Fig. 7 and ESI†). They suggest a disordered complex, as a single complex cannot justify the results obtained. The STD signals were compatible with magnetization arising from all the spatial directions: top, down, left and right. This can be explained when several complex




Fig. 6 Top: Puckering coordinates (θ) for the different pyranose rings (A–D) of tetrasaccharide **3** during a MD-tar simulation of 8 ns. Bottom: Trajectories of the glycosidic angles (ϕ, ψ) for each glycosidic linkage of the compound **3** along a 8 ns MD-tar simulation.




Fig. 7 Binding epitopes of **3** (A) and **1** (B) from STD NMR experiments with midkine.

geometries are coexisting in the binding site. Similar STD results were obtained for the interaction between natural CS tetrasaccharides and midkine.¹⁴

Conclusions

We have developed a synthetic approach for the preparation of a new type of CS analogues where the GlcA units were replaced



by more easily accessible glucose moieties. The designed protecting group strategy allowed us to control the stereochemistry of the glycosidic bonds and introduce the sulfate groups at positions corresponding to biologically active CS-E. Although glucose containing building blocks showed only moderate reactivity in 2 + 2 and 2 + 3 coupling reactions, tetrasaccharide **1** and pentasaccharide **2** were successfully synthesized.

Experimental $^3J_{\text{HH}}$ coupling constants and NOE-derived interprotonic distances for the synthesized oligosaccharides were consistent with a 3D structure in which all the monosaccharide rings adopt 4C_1 chair conformations and the glycosidic linkages present syn- Ψ dispositions. MD simulations supported the NMR experimental data, indicating a 3D shape similar to the natural CS-E oligosaccharide structure.

On the other hand, FP competition assays demonstrated that the synthesized oligosaccharides lacking the carboxylate functions of GlcA units were able to mimic CS-E sequences and interact with growth factor midkine in the micromolar range, suggesting that the CO_2^- group is not essential for the interaction. Our data also showed that sulfated intermediates 3–6 were more potent inhibitors, confirming that the presence of hydrophobic substituents strongly enhanced the binding. The interaction was also demonstrated by STD-NMR experiments. We found that the STD effects were extended along the entire sugar chain. These results are compatible with the coexistence of random sugar orientations, without a dominant one, in the protein binding site.

In summary, the reported oligosaccharides can be considered as functional and structural CS-E mimetics with potential applications in the study of CS-protein interactions and the modulation of the corresponding biological processes.

Experimental

General synthetic procedures

Thin layer chromatography (TLC) analyses were performed on silica gel 60 F₂₅₄ precoated on aluminium plates (Merck) and the compounds were detected by staining with cerium(IV) sulfate (1 g)/ammonium molybdate tetrahydrate (21 g)/sulfuric acid (30 mL) solution in water (0.47 L) or with anisaldehyde solution [anisaldehyde (25 mL) with sulfuric acid (25 mL), ethanol (450 mL) and acetic acid (1 mL)], followed by heating at over 200 °C. Column chromatography was carried out on silica gel 60 (0.2–0.063 mm or 0.040–0.015 mm; Merck). Optical rotations were determined with a PerkinElmer 341 polarimeter. ^1H -, ^{19}F - and ^{13}C -NMR spectra were acquired on a Bruker Avance III-400 spectrometer. Unit A refers to the reducing end monosaccharide in the NMR data. Electrospray mass spectra (ESI MS) were carried out with an Esquire 6000 ESI-Ion Trap from Bruker Daltonics. High resolution mass spectra (HR MS) were carried out by CITIUS (Universidad de Sevilla). Microwave-based sulfation reactions were performed using a Biotage Initiator Eight synthesizer in sealed reaction vessels.

4-Methoxyphenyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido- β -D-galactopyranosyl)-(1 \rightarrow 4)-2-O-benzoyl-3-O-benzyl-6-O-pivaloyl- β -D-glucopyranoside (9). Donor **7** (148 mg, 0.27 mmol) and acceptor **8** (102 mg, 0.18 mmol) were coevaporated with toluene, concentrated *in vacuo* and dissolved in dry CH_2Cl_2 (2.5 mL) in the presence of freshly activated 4 Å molecular sieves (225 mg). After stirring for 15 min at 0 °C, TMSOTf (250 μL of a 0.22 M solution in dry CH_2Cl_2) was added under an argon atmosphere. After stirring for 1.5 h at 0 °C, the reaction mixture was neutralized with Et_3N , filtered, and concentrated to dryness. The residue was purified by column chromatography (toluene–EtOAc 3 : 1) to afford **9** as a colorless oil (141 mg, 82%). TLC (toluene–EtOAc 3 : 1) Rf 0.25; $[\alpha]_{\text{D}}^{20} +5^\circ$ (*c* 1.0, CHCl_3); ^1H -NMR (400 MHz, CDCl_3): δ 7.99 (d, 2H, Ar), 7.68 (d, 1H, $J_{\text{NH},2} = 9.6$ Hz, NH), 7.60 (t, 1H, Ar), 7.46 (m, 2H, Ar), 7.29–7.15 (m, 5H, Ar), 6.92 (m, 2H, Ar), 6.75 (m, 2H, Ar), 5.47 (t, 1H, $J_{1,2} = J_{2,3} = 8.3$ Hz, H-2), 5.36 (d, 1H, $J_{3,4} = 2.6$ Hz, H-4'), 5.10 (dd, 1H, $J_{2,3} = 11.2$ Hz, H-3'), 5.02 (d, 1H, H-1), 4.93–4.68 (2d, 2H, $\text{CH}_2(\text{Bn})$), 4.61 (d, 1H, $J_{1,2} = 8.3$ Hz, H-1'), 4.41–4.31 (m, 3H, H-2', 2 \times H-6), 4.03–3.85 (m, 5H, H-3, H-4, H-5', 2 \times H-6'), 3.75 (m, 4H, H-5, Me (OMP)), 2.16–2.03 (3s, 9H, OAc), 1.27 (s, 9H, $\text{C}(\text{CH}_3)_3$); ^{13}C -NMR (100 MHz, CDCl_3): δ 179.3, 170.5, 170.3, 170.1, 165.1 (5 \times CO), 157.8 (q, $J_{\text{C},\text{F}} = 37.9$ Hz, COCF_3), 155.6–114.4 (Ar), 115.8 (q, COCF_3), 100.9 (C-1'), 100.6 (C-1), 79.9, 77.5 (C-3, C-4), 74.8 ($\text{CH}_2(\text{Bn})$), 73.5 (C-5), 72.8 (C-2), 71.0 (C-5'), 69.9 (C-3'), 66.1 (C-4'), 62.7 (C-6), 60.8 (C-6'), 55.6 (Me (OMP)), 51.5 (C-2'), 39.0 ($\text{C}(\text{CH}_3)_3$), 27.1 ($\text{C}(\text{CH}_3)_3$), 20.6–20.4 (3 \times CH_3); HR MS: *m/z*: calcd for $\text{C}_{46}\text{H}_{52}\text{F}_3\text{NO}_{17}\text{Na}$: 970.3080; found: 970.3088 [$M + \text{Na}$] $^+$.

4-Methoxyphenyl O-(2-deoxy-2-trifluoroacetamido- β -D-galactopyranosyl)-(1 \rightarrow 4)-2-O-benzoyl-3-O-benzyl-6-O-pivaloyl- β -D-glucopyranoside (10). Compound **9** (3.31 g, 3.48 mmol) was dissolved in $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (30 mL/3.3 mL) and *p*-toluenesulfonic acid was added (2.02 g, 10.4 mmol). After stirring for 17 h at room temperature, the reaction mixture was diluted with CH_2Cl_2 and washed with saturated aqueous NaHCO_3 and brine. The organic phase was dried (MgSO_4), filtered and concentrated to dryness. The residue was purified by column chromatography (CH_2Cl_2 –MeOH 20 : 1) to afford **10** as a white amorphous solid (1.99 g, 69%). TLC (CH_2Cl_2 –MeOH 20 : 1) Rf 0.27; $[\alpha]_{\text{D}}^{20} +41^\circ$ (*c* 1.0, CHCl_3); ^1H -NMR (400 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$ 9 : 1): δ 7.97 (d, 2H, Ar), 7.61 (t, 1H, Ar), 7.46 (m, 2H, Ar), 7.20–7.05 (m, 5H, Ar), 6.87 (m, 2H, Ar), 6.71 (m, 2H, Ar), 5.33 (t, 1H, $J_{1,2} = J_{2,3} = 9.0$ Hz, H-2), 5.00 (m, 2H, H-1, $\text{CH}_2(\text{Bn})$), 4.60 (d, 1H, $\text{CH}_2(\text{Bn})$), 4.42 (d, 1H, $J_{1,2} = 8.2$ Hz, H-1'), 4.35 (br d, 1H, $J_{6,6} = 11.4$ Hz, H-6), 4.13 (m, 2H, H-6, H-2'), 3.98 (t, 1H, $J_{3,4} = J_{4,5} = 9.3$ Hz, H-4), 3.90–3.80 (m, 3H, H-3, H-4', H-6'), 3.75–3.71 (m, 4H, H-5, Me (OMP)), 3.64 (dd, 1H, $J_{3,4} = 2.9$ Hz, $J_{2,3} = 10.7$ Hz, H-3'), 3.56 (br d, 1H, H-6'), 3.44 (m, 1H, H-5'), 1.24 (s, 9H, $\text{C}(\text{CH}_3)_3$); ^{13}C -NMR (100 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$ 9 : 1): δ 179.2, 165.5 (2 \times CO), 158.6 (q, $J_{\text{C},\text{F}} = 37.9$ Hz, COCF_3), 155.5–114.4 (Ar), 116.1 (q, $J_{\text{C},\text{F}} = 287.9$ Hz, COCF_3), 100.6 (C-1'), 100.3 (C-1), 80.5 (C-3), 76.6 (C-5'), 76.2 ($\text{CH}_2(\text{Bn})$), 75.7 (C-4), 73.5 (C-5), 72.6 (C-2), 70.6 (C-3'), 68.5 (C-4'), 62.9 (C-6), 62.1 (C-6'), 55.5 (Me (OMP)), 53.8 (C-2'), 38.9 ($\text{C}(\text{CH}_3)_3$), 26.9 ($\text{C}(\text{CH}_3)_3$); HR MS:



m/z : calcd for $C_{40}H_{46}F_3NO_{14}Na$: 844.2763; found: 844.2754 $[M + Na]^+$.

4-Methoxyphenyl O-(2-deoxy-4,6-O-di-*tert*-butylsilylene-2-trifluoroacetamido- β -D-galactopyranosyl)-(1 \rightarrow 4)-2-O-benzoyl-3-O-benzyl-6-O-pivaloyl- β -D-glucopyranoside (11). Compound **10** (1.06 g, 1.29 mmol) was dissolved in dry pyridine (Py, 26 mL) and cooled (0 °C). Di-*tert*-butylsilyl bis(trifluoromethanesulfonate) (518 μ L, 1.54 mmol) was added at 0 °C and the mixture was stirred at room temperature for 30 min. The reaction was quenched with MeOH (5.2 mL), diluted with EtOAc (300 mL), and washed with 1 M HCl, saturated aqueous $NaHCO_3$, and brine. The organic phase was dried ($MgSO_4$), filtered and concentrated to dryness. The residue was purified by column chromatography (toluene–EtOAc 4 : 1) to afford **11** as a white amorphous solid (1.17 g, 94%). TLC (toluene–EtOAc 3 : 1) Rf 0.28; $[\alpha]_D^{20} +9^\circ$ (c 1.0, $CHCl_3$); 1H -NMR (400 MHz, $CDCl_3$): δ 7.91 (m, 2H, Ar), 7.56 (t, 1H, Ar), 7.49 (d, 1H, $J_{2,NH} = 9.2$ Hz, NH), 7.41 (t, 2H, Ar), 7.23–7.04 (m, 5H, Ar), 6.87 (m, 2H, Ar), 6.73 (m, 2H, Ar), 5.41 (t, 1H, H-2), 4.98 (d, 1H, $J_{1,2} = 7.6$ Hz, H-1), 4.95 (d, 1H, $CH_2(Bn)$), 4.66 (m, 2H, H-6a, $CH_2(Bn)$), 4.39 (d, 1H, $J_{3,4} = 3.3$ Hz, H-4'), 4.36 (d, 1H, $J_{1,2} = 8.5$ Hz, H-1'), 4.29 (m, 1H, H-2'), 4.24–4.15 (m, 3H, H-6b, H-6'a, H-6'b), 3.88 (t, 1H, $J_{2,3} = J_{3,4} = 8.0$ Hz, H-3), 3.78–3.68 (m, 5H, H-4, Me (OMP), H-5), 3.55 (ddd, $J_{2,3} = 10.8$ Hz, H-3'), 3.33 (br s, 1H, H-5'), 2.73 (d, 1H, $J_{3,OH} = 11.7$ Hz, OH), 1.22 (s, 9H, $C(CH_3)_3$), 1.05, 1.04 (2s, 18H, $Si(C(CH_3)_3)_2$); ^{13}C -NMR (100 MHz, $CDCl_3$): δ 179.7, 165.3 (2 \times CO), 158.4 (q, $J_{C,F} = 37.0$ Hz, $COCF_3$), 155.7–114.6 (Ar), 116.1 (q, $J_{C,F} = 288.0$ Hz, $COCF_3$), 102.6 (C-1'), 100.4 (C-1), 80.7 (C-3), 79.8 (C-4), 75.1 ($CH_2(Bn)$), 73.7 (C-5), 73.1 (C-2), 72.2 (C-3', C-5'), 71.8 (C-4'), 66.6 (C-6'), 62.6 (C-6), 55.7 (Me (OMP)), 53.7 (C-2'), 39.2 ($C(CH_3)_3$), 27.7, 27.5 ($Si(C(CH_3)_3)_2$), 27.3 ($C(CH_3)_3$), 23.5, 20.7 ($Si(C(CH_3)_3)_2$); HR MS: m/z : calcd for $C_{48}H_{62}F_3NO_{14}NaSi$: 984.3784; found: 984.3776 $[M + Na]^+$.

O-(2-Deoxy-3-O-levulinoyl-4,6-O-di-*tert*-butylsilylene-2-trifluoroacetamido- β -D-galactopyranosyl)-(1 \rightarrow 4)-2-O-benzoyl-3-O-benzyl-6-O-pivaloyl- α,β -D-glucopyranose (12). Lev₂O preparation: LevOH (527 μ L, 5.06 mmol) was added at 0 °C to a solution of 1,3-dicyclohexylcarbodiimide (527 mg, 2.53 mmol) in CH_2Cl_2 (9.5 mL). After stirring for 5 min at room temperature, the mixture was cooled and filtered, and the urea precipitate was washed with additional CH_2Cl_2 (3.5 mL) to give 13 mL of a 0.19 M Lev₂O solution.

Lev₂O (13 mL of a 0.19 M solution in CH_2Cl_2) was added at room temperature to a mixture of **11** (811 mg, 0.843 mmol) and DMAP (16 mg, 0.13 mmol). The mixture was stirred for 1.5 h, diluted with CH_2Cl_2 , and washed with saturated aqueous $NaHCO_3$, and brine. The organic phase was dried ($MgSO_4$), filtered and concentrated to dryness to give the corresponding levulinated disaccharide that was directly used in the next step without further purification.

CAN (5.0 mL of a 0.67 M solution in H_2O) was added to a solution of the levulinated compound (0.843 mmol) in $CH_2Cl_2/MeCN$ (1 : 2; 45 mL). After stirring for 2 h at room temperature, the reaction mixture was diluted with EtOAc, washed with H_2O , saturated aqueous $NaHCO_3$, and brine. The organic phase was dried ($MgSO_4$), filtered and concentrated to

dryness. The residue was purified by column chromatography (CH_2Cl_2 –MeOH 80 : 1 \rightarrow CH_2Cl_2 –MeOH 70 : 1) to afford **12** as light yellow foam (704 mg, 88%, two steps, mixture of α/β anomers). TLC (CH_2Cl_2 –MeOH 30 : 1) Rf 0.31, 0.41; 1H -NMR (400 MHz, $CDCl_3$) (data for α anomer): δ 7.93 (m, 2H, Ar), 7.55 (m, 1H, Ar), 7.46 (d, 1H, $J_{2,NH} = 9.0$ Hz, NH), 7.41 (m, 2H, Ar), 7.24–7.10 (m, 5H, Ar), 5.48 (t, 1H, $J_{1,2} = J_{1,OH} = 3.8$ Hz, H-1), 5.09–4.99 (m, 2H, $CH_2(Bn)$, H-2), 4.76–4.59 (m, 3H, $CH_2(Bn)$, H-3', H-6a), 4.59–4.50 (m, 3H, H-2', H-4', H-1'), 4.21 (dd, 1H, H-3), 4.18–4.05 (m, 4H, H-5, H-6b, H-6'a, H-6'b), 3.63 (m, 1H, H-4), 3.28 (br s, 1H, H-5'), 2.90 (d, 1H, OH), 2.76–2.57 (m, 4H, $CH_2(Lev)$), 2.18 (s, 3H, $CH_3(Lev)$), 1.25 (s, 9H, $C(CH_3)_3$), 1.06, 1.01 (2s, 18H, $Si(C(CH_3)_3)_2$); ^{13}C -NMR (100 MHz, $CDCl_3$) (data for α anomer): δ 206.5, 179.6, 172.6, 165.9 (4 \times CO), 157.8 (q, $J_{C,F} = 37.2$ Hz, $COCF_3$), 138.6–127.4 (Ar), 116.0 (q, $J_{C,F} = 288.1$ Hz, $COCF_3$), 102.4 (C-1'), 90.1 (C-1), 79.8 (C-4), 77.9 (C-3), 75.0 ($CH_2(Bn)$), 73.7, 73.5 (C-2 and C-3'), 71.8 (C-5'), 69.5 (C-4'), 69.1 (C-5), 66.6 (C-6'), 62.1 (C-6), 50.6 (C-2'), 39.3 ($C(CH_3)_3$), 37.9 ($CH_2(Lev)$), 29.8 ($CH_3(Lev)$), 28.3 ($CH_2(Lev)$), 27.7, 27.5 ($Si(C(CH_3)_3)_2$), 27.4 ($C(CH_3)_3$), 23.4, 20.7 ($Si(C(CH_3)_3)_2$); HR MS: m/z : calcd for $C_{46}H_{62}F_3NO_{15}NaSi$: 976.3733; found: 976.3725 $[M + Na]^+$.

O-[O-(2-Deoxy-3-O-levulinoyl-4,6-O-di-*tert*-butylsilylene-2-trifluoroacetamido- β -D-galactopyranosyl)-(1 \rightarrow 4)-2-O-benzoyl-3-O-benzyl-6-O-pivaloyl- α,β -D-glucopyranosyl] trichloroacetimidate (13). Trichloroacetonitrile (2.71 mL, 26.5 mmol) and K_2CO_3 (88 mg, 0.64 mmol) were added to **12** (506 mg, 0.53 mmol) in dry CH_2Cl_2 (8.5 mL) under an argon atmosphere. After stirring at room temperature for 14 h, the mixture was filtered and concentrated to dryness. The residue was purified by chromatography on a short column of silica gel (hexane/EtOAc 2 : 1 + 1% Et_3N) to afford **13** as a white foam (545 mg, 94%, mixture of α/β anomers). TLC (CH_2Cl_2 –MeOH 50 : 1) Rf 0.36 and 0.31; 1H -NMR (400 MHz, $CDCl_3$) (data for β anomer): δ 8.58 (s, 1H, NH), 7.91 (m, 2H, Ar), 7.55 (m, 1H, Ar), 7.43–7.36 (m, 3H, Ar, NH), 7.23–7.10 (m, 5H, Ar), 5.97 (d, 1H, $J_{1,2} = 6.6$ Hz, H-1), 5.50 (t, 1H, $J_{2,3} = 6.9$ Hz, H-2), 4.87 (d, 1H, $CH_2(Bn)$), 4.79 (dd, 1H, $J_{2,3} = 11.0$ Hz, $J_{3,4} = 3.1$ Hz, H-3'), 4.74 (d, 1H, $CH_2(Bn)$), 4.61–4.45 (m, 4H, H-1', H-4', H-6a, H-2'), 4.26 (dd, 1H, $J_{5,6a} = 2.3$ Hz, $J_{6a,6b} = 11.9$ Hz, H-6b), 4.14–4.05 (m, 2H, H-6'a, H-6'b), 3.95 (t, 1H, $J_{3,4} = 6.8$ Hz, H-3), 3.87–3.82 (m, 2H, H-4, H-5), 3.30 (br s, 1H, H-5'), 2.74, 2.58 (2 m, 4H, $CH_2(Lev)$), 2.17 (s, 3H, $CH_3(Lev)$), 1.22 (s, 9H, $C(CH_3)_3$), 1.01, 1.00 (2s, 18H, $Si(C(CH_3)_3)_2$); ESI MS: m/z : calcd for $C_{48}H_{62}Cl_3F_3N_2O_{15}SiNa$: 1119.3; found: 1119.3 $[M + Na]^+$.

4-Methoxyphenyl O-(2-deoxy-3-O-levulinoyl-4,6-O-di-*tert*-butylsilylene-2-trifluoroacetamido- β -D-galactopyranosyl)-(1 \rightarrow 4)-O-(2-O-benzoyl-3-O-benzyl-6-O-pivaloyl- β -D-glucopyranosyl)-(1 \rightarrow 3)-O-(2-deoxy-4,6-O-di-*tert*-butylsilylene-2-trifluoroacetamido- β -D-galactopyranosyl)-(1 \rightarrow 4)-2-O-benzoyl-3-O-benzyl-6-O-pivaloyl- β -D-glucopyranoside (14). Donor **13** (136 mg, 0.124 mmol) and acceptor **11** (40 mg, 0.042 mmol) were coevaporated with toluene, concentrated *in vacuo* and dissolved in dry CH_2Cl_2 (1.8 mL) in the presence of freshly activated 4 Å molecular sieves (135 mg). After stirring for 15 min at room temperature, TBSOTf (190 μ L of a 0.13 M solution in dry



CH₂Cl₂) was added under an argon atmosphere. After 40 min, the reaction mixture was neutralized with Et₃N, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography (toluene–acetone 9 : 1) and Sephadex LH 20 chromatography (CH₂Cl₂–MeOH 1 : 1) to obtain **14** as a white amorphous solid (37 mg, 47%). TLC (toluene–acetone 6 : 1) R_f 0.49; $[\alpha]_D^{20} +24^\circ$ (*c* 1.0, CHCl₃); ¹H-NMR (400 MHz, CDCl₃): δ 7.94 (m, 4H, Ar), 7.55 (m, 2H, Ar), 7.40 (m, 4H, Ar), 7.20–7.07 (m, 12H, 2NH, Ar), 6.86 (m, 2H, Ar), 6.70 (m, 2H, Ar), 5.44 (t, 1H, *J*_{1,2} = *J*_{2,3} = 7.6 Hz, H-2A or C), 5.15 (t, 1H, *J*_{1,2} = *J*_{2,3} = 7.4 Hz, H-2A or C), 5.00 (m, 2H, H-1A, H-1C), 4.84 (m, 4H, H-1B, H-3D, CH₂(Bn)), 4.71 (d, 1H, CH₂(Bn)), 4.61 (m, 2H, H-1D, CH₂(Bn)), 5.54 (d, 1H, *J*_{3,4} = 3.1 Hz, H-4D), 4.48 (d, 1H, *J*_{3,4} = 2.5 Hz, H-4B), 4.42 (m, 3H, H-2D, H-6aA, H-6aC), 4.32 (dd, 1H, *J*_{5,6b} = 4.7 Hz, *J*_{6a,6b} = 12.1 Hz, H-6bA or C), 4.20–4.02 (m, 4H, H-6bA or C, H-6aD, H-2B, H-6bD), 3.99–3.92 (m, 4H, H-6aB, H-6bB, H-3B, H-3A or C), 3.84–3.79 (m, 2H, H-3A or C, H-4A or C), 3.77–3.71 (m, 5H, H-4A or C, H-5A or C, Me (OMP)), 3.62 (m, 1H, H-5A or C), 3.29 (br s, 1H, H-5D), 3.07 (br s, 1H, H-5B), 2.75 (m, 2H, CH₂(Lev)), 2.59 (m, 2H, CH₂(Lev)), 2.17 (s, 3H, CH₃(Lev)), 1.21, 1.17 (2s, 18H, C(CH₃)₃), 1.00, 0.97, 0.92 (3s, 36H, Si(C(CH₃)₃)₂); ¹³C-NMR (100 MHz, CDCl₃): δ 206.5, 179.1, 178.3, 172.8, 165.3 (6 × CO), 157.8 (2q, COCF₃), 155.6–114.5 (Ar), 115.9, 115.7 (2q, COCF₃), 101.6 (C-1D), 101.1 (C-1B), 100.2, 100.0 (C-1A, C-1C), 80.9, 80.5 (C-3A, C-3C), 78.6, 78.0 (C-4A, C-4C), 75.5 (C-3B), 74.6 (C-5A or C), 74.2 (CH₂(Bn)), 73.8, 73.7 (C-5A or C, CH₂(Bn)), 73.4, 73.1 (C-2A, C-2C), 72.8 (C-3D), 72.3 (C-4B), 71.9 (C-5B, C-5D), 69.5 (C-4D), 66.8, 66.6 (C-6B, C-6D), 63.5, 62.8 (C-6A, C-6C), 55.7 (Me (OMP)), 52.9 (C-2B), 51.0 (C-2D), 39.1, 38.9 (C(CH₃)₃), 38.0 (CH₂(Lev)), 29.8 (CH₃(Lev)), 28.3 (CH₂(Lev)), 27.7, 27.6, 27.4, 27.2 (Si(C(CH₃)₃)₂), C(CH₃)₃, 23.4, 23.3, 20.7, 20.6 (Si(C(CH₃)₃)₂); ¹⁹F NMR (376 MHz, CDCl₃): δ –75.6 (s, 3F), –75.7 (s, 3F); HR MS: *m/z*: calcd for C₉₄H₁₂₂F₆N₂O₂₈Si₂Na: 1919.7519; found: 1919.7500 [M + Na]⁺.

4-Methoxyphenyl O-(2-deoxy-3-O-levulinoyl-2-trifluoroacetamido-β-D-galactopyranosyl)-(1 → 4)-O-(2-O-benzoyl-3-O-benzyl-6-O-pivaloyl-β-D-glucopyranosyl)-(1 → 3)-O-(2-deoxy-2-trifluoroacetamido-β-D-galactopyranosyl)-(1 → 4)-2-O-benzoyl-3-O-benzyl-6-O-pivaloyl-β-D-glucopyranoside (15). An excess of (HF)_{*n*}Py (88 μL, 3.4 mmol) was added at 0 °C under an argon atmosphere to a solution of **14** (32 mg, 17 μmol) in dry THF (1.7 mL). After 24 h at 0 °C the mixture was diluted with CH₂Cl₂ and washed with H₂O, saturated NaHCO₃ solution and H₂O. The organic layers were dried (MgSO₄), filtered and concentrated *in vacuo* to give **15** (27 mg, 99%) as a white amorphous solid. TLC (toluene–acetone 3 : 2) R_f 0.26; ¹H-NMR (400 MHz, CDCl₃/CD₃OD 4 : 1): δ 7.95 (m, 4H, Ar), 7.58 (m, 2H, Ar), 7.43 (m, 4H, Ar), 7.16–7.01 (m, 10H, Ar), 6.83 (m, 2H, Ar), 6.67 (m, 2H, Ar), 5.28 (dd, 1H, *J*_{1,2} = 8.0 Hz, *J*_{2,3} = 9.7 Hz, H-2A), 5.06 (dd, 1H, *J*_{1,2} = 7.9 Hz, *J*_{2,3} = 9.6 Hz, H-2C), 4.98–4.93 (m, 3H, CH₂(Bn), H-1A), 4.86 (dd, 1H, *J*_{2,3} = 11.1 Hz, *J*_{3,4} = 3.1 Hz, H-3D), 4.72 (d, 1H, H-1C), 4.53–4.41 (m, 5H, H-1D, CH₂(Bn), H-6aA or C, H-2D), 4.40 (d, 1H, *J*_{1,2} = 8.2 Hz, H-1B), 4.22 (br d, 1H, H-6aA or C), 4.11 (br t, 1H, H-2B), 4.05–3.90 (m, 6H, H-6bA, H-6bC, H-4D, H-4B, H-4A, H-4C), 3.87–3.75 (m, 5H,

H-6aB, H-6aD, H-3C, H-3A, H-3B), 3.68 (s, 3H, Me (OMP)), 3.64–3.58 (m, 2H, H-5A, H-5C), 3.52–3.45 (m, 3H, H-6bB, H-6bD, H-5B or D), 3.39 (m, 1H, H-5B or D), 2.75 (m, 2H, CH₂(Lev)), 2.53 (m, 2H, CH₂(Lev)), 2.15 (s, 3H, CH₃(Lev)), 1.21, 1.17 (2s, 18H, C(CH₃)₃); ¹³C-NMR (100 MHz, CDCl₃/CD₃OD 4 : 1): δ 208.7, 179.3, 172.6, 165.8, 165.7 (6 × CO), 158.0 (2q, COCF₃), 155.7–114.6 (Ar), 116.2 (q, *J*_{C,F} = 287.1 Hz, COCF₃), 115.9 (q, *J*_{C,F} = 287.7 Hz, COCF₃), 101.3 (C-1C), 100.5 (C-1A, C-1D), 100.3 (C-1B), 80.9 (C-3A), 80.6 (C-3C), 79.3 (C-3B), 76.7, 76.6, 76.5 (2 × CH₂(Bn), C-5B, C-5D), 75.4, 75.1 (C-4A, C-4C), 73.8, 73.6 (C-5A, C-5C), 73.1 (C-3D), 72.9 (C-2C), 72.8 (C-2A), 68.1 (C-4B), 66.2 (C-4D), 62.9, 62.5, 62.3, 62.2 (C-6A, C-6B, C-6C, C-6D), 55.7 (Me (OMP)), 52.3 (C-2B), 51.2 (C-2D), 39.2, 39.1 (C(CH₃)₃), 38.1 (CH₂(Lev)), 29.8 (CH₃(Lev)), 28.1 (CH₂(Lev)), 27.1 (C(CH₃)₃); HR MS: *m/z*: calcd for C₇₈H₉₀F₆N₂O₂₈Na: 1639.5477; found: 1639.5465 [M + Na]⁺.

4-Methoxyphenyl O-(2-deoxy-3-O-levulinoyl-4,6-di-O-sulfo-2-trifluoroacetamido-β-D-galactopyranosyl)-(1 → 4)-O-(2-O-benzoyl-3-O-benzyl-6-O-pivaloyl-β-D-glucopyranosyl)-(1 → 3)-O-(2-deoxy-4,6-di-O-sulfo-2-trifluoroacetamido-β-D-galactopyranosyl)-(1 → 4)-2-O-benzoyl-3-O-benzyl-6-O-pivaloyl-β-D-glucopyranoside (5). Compound **15** (38 mg, 24 μmol) and sulfur trioxide–trimethylamine complex (131 mg, 0.94 mmol) were dissolved in dry DMF (3.5 mL) and heated at 100 °C for 30 min using microwave radiation (35 W average power). The reaction vessel was cooled and Et₃N (300 μL), MeOH (1.5 mL) and CH₂Cl₂ (1.5 mL) were added. The solution was first purified by Sephadex LH 20 chromatography (CH₂Cl₂–MeOH 1 : 1). The residue was then purified by silica gel column chromatography (EtOAc–MeOH–H₂O 36 : 5 : 3 → EtOAc–MeOH–H₂O 24 : 5 : 3) and finally eluted from a Dowex 50WX2–Na⁺ column (MeOH) to obtain **5** as sodium salt (40 mg, 84%, white amorphous solid). TLC (EtOAc–MeOH–H₂O 24 : 5 : 3) R_f 0.28; ¹H-NMR (400 MHz, CD₃OD): δ 7.97 (m, 4H, Ar), 7.62 (m, 2H, Ar), 7.46 (m, 4H, Ar), 7.20–7.02 (m, 10H, Ar), 6.84 (m, 2H, Ar), 6.72 (m, 2H, Ar), 5.27 (br t, 1H, H-2A), 5.25 (t, 1H, *J*_{2,3} = 9.8 Hz, H-2C), 5.13 (d, 1H, *J*_{1,2} = 7.9 Hz, H-1A), 5.05 (dd, 1H, *J*_{2,3} = 11.3 Hz, *J*_{3,4} = 3.3 Hz, H-3D), 4.99 (2d, 2H, CH₂(Bn)), 4.90 (m, 2H, H-4B, H-4D), 4.78 (d, 1H, *J*_{1,2} = 7.8 Hz, H-1C), 4.75 (d, 1H, *J*_{1,2} = 8.3 Hz, H-1D), 4.70 (d, 1H, *J*_{1,2} = 8.1 Hz, H-1B), 4.61 (d, 1H, CH₂(Bn)), 4.55 (d, 1H, CH₂(Bn)), 4.45–4.30 (m, 5H, H-6aA, H-6aB, H-6aC, H-6aD, H-2D), 4.30–4.07 (m, 5H, H-6bA, H-6bB, H-6bC, H-6bD, H-2B), 4.07–3.96 (m, 5H, H-4A, H-4C, H-3A, H-3B, H-5B or D), 3.90 (t, 1H, H-3C), 3.88–3.82 (m, 2H, H-5B or D, H-5A or C), 3.76 (m, 1H, H-5A or C), 3.68 (s, 3H, Me (OMP)), 3.31 (m, 2H, CH₂(Lev)), 2.59 (m, 2H, CH₂(Lev)), 2.13 (s, 3H, CH₃(Lev)), 1.25, 1.20 (2s, 18H, C(CH₃)₃); ¹³C-NMR (100 MHz, CD₃OD): δ 209.7, 180.1, 179.7, 173.9, 167.6, 167.1 (6 × CO), 159.4 (q, *J*_{C,F} = 37.1 Hz, COCF₃), 159.2 (q, *J*_{C,F} = 37.4 Hz, COCF₃), 156.9–115.4 (Ar), 117.4 (q, *J*_{C,F} = 287.3 Hz, COCF₃), 117.2 (q, *J*_{C,F} = 288.2 Hz, COCF₃), 102.5 (C-1C), 101.3 (C-1D), 101.1 (C-1A), 101.0 (C-1B), 81.1 (C-3C), 80.9 (C-3A), 77.9 (C-4A), 77.2 (C-4C), 76.8 (C-4B), 76.4 (C-3B), 76.1, 75.4 (2 × CH₂(Bn), 75.0 (C-5A or C), 74.7, 74.6, 74.4 (C-5A or C, C-5B or D, C-2C, C-2A), 74.0 (C-5B or D), 72.4 (C-4D), 71.9 (C-3D), 68.5, 67.9 (C-6B, C-6D), 64.4, 64.2 (C-6A, C-6C), 56.0 (Me (OMP)), 54.1



(C-2B), 52.5 (C-2D), 40.0, 39.9 (C(CH₃)₃), 38.5 (CH₂(Lev)), 29.6 (CH₃(Lev)), 29.2 CH₂(Lev), 27.8, 27.6 (C(CH₃)₃); ¹⁹F NMR (376 MHz, CD₃OD): δ -76.5 (s, 3F), -77.1 (s, 3F); ESI MS: *m/z*: calcd for C₇₈H₈₆F₆N₂O₄₀S₄Na₃: 2001.3; found: 2000.7 [*M* + 3Na]⁻.

4-Methoxyphenyl O-(2-acetamido-2-deoxy-4,6-di-O-sulfo-β-D-galactopyranosyl)-(1 → 4)-O-(3-O-benzyl-β-D-glucopyranosyl)-(1 → 3)-O-(2-acetamido-2-deoxy-4,6-di-O-sulfo-β-D-galactopyranosyl)-(1 → 4)-3-O-benzyl-β-D-glucopyranoside (3). H₂O₂ (30%, 412 μL) and an aqueous solution of LiOH (0.7 M, 252 μL) were added at 0 °C to a solution of **5** (21 mg, 10.4 μmol) in THF (1.1 mL). After stirring for 24 h at room temperature, MeOH (2.1 mL) and an aqueous solution of NaOH (4 M, 519 μL) were added. After stirring for 72 h at room temperature, the reaction mixture was neutralized with Amberlite IR-120 (H⁺) resin, filtered, and concentrated to give the desired diamine intermediate. Triethylamine (38 μL, 0.27 mmol) and acetic anhydride (39 μL, 0.42 mmol) were added to a cooled (0 °C) solution of this diamine derivative in MeOH (2.8 mL). Additional portions of triethylamine (2 × 0.27 mmol) and acetic anhydride (2 × 0.42 mmol) were added every 2 hours to complete the reaction. After stirring for 7 h at room temperature, Et₃N (300 μL) was added and the mixture was concentrated to dryness. The residue was purified by Sephadex LH 20 chromatography column which was eluted with H₂O–MeOH (9 : 1) to obtain **3**. This compound was then dissolved in H₂O (2 mL) and Amberlite IR-120 H⁺ resin was added (pH 3.0). The mixture was immediately filtered, treated with 0.04 M NaOH (pH 7.1) and lyophilised. The white solid was finally eluted from a column of Dowex 50WX4-Na⁺ (H₂O) to obtain **3** as sodium salt (12.8 mg, 85%). TLC (EtOAc–MeOH–H₂O 12 : 5 : 3) R_f 0.40; ¹H-NMR (400 MHz, D₂O): δ 7.61–7.38 (m, 10H, Ar), 7.13 (m, 2H, Ar), 7.00 (m, 2H, Ar), 5.05 (m, 2H, H-1A, CH₂(Bn)), 4.98 (d, 1H, CH₂(Bn)), 4.94 (d, 1H, *J*_{3,4} = 2.8 Hz, H-4B), 4.88, 4.85 (2d, 2H, CH₂(Bn)), 4.74 (d, 1H, *J*_{3,4} = 3.3 Hz, H-4D), 4.73 (d, 1H, *J*_{1,2} = 8.5 Hz, H-1B), 4.65 (d, 1H, *J*_{1,2} = 8.2 Hz, H-1D), 4.53 (d, 1H, *J*_{1,2} = 7.9 Hz, H-1C), 4.26 (dd, 1H, *J*_{5,6a} = 4.7 Hz, *J*_{6a,6b} = 11.0 Hz, H-6aB or D), 4.21 (dd, 1H, *J*_{5,6a} = 4.0 Hz, *J*_{6a,6b} = 11.2 Hz, H-6aB or D), 4.17–4.11 (m, 2H, H-2B, H-6bB or D), 4.08–3.87 (m, 10H, H-6bB or D, H-3B, H-2D, H-5B, H-5D, H-4A, H-4C, H-6aA, H-6aC, H-3D), 3.83 (s, 3H, Me (OMP)), 3.81 (t, 1H, *J*_{1,2} = *J*_{2,3} = 9.1 Hz, H-3A), 3.76–3.67 (m, 5H, H-6bA, H-6bC, H-2A, H-5A, H-3C), 3.54 (br t, 1H, H-2C), 3.51 (m, 1H, H-5C), 2.07, 2.06 (2s, 6H, NHAc); ¹³C-NMR (100 MHz, D₂O; selected data from HSQC experiment): δ 104.0 (C-1C), 100.8 (C-1A), 100.5 (C-1D), 100.0 (C-1B), 81.3 (C-3A, C-3C), 76.4 (C-3B), 76.1 (C-4B), 75.2 (C-4D), 75.1 (C-5A), 75.0 (C-4C), 74.9 (C-4A), 74.8 (C-5C), 73.9, 73.3 (2 × CH₂(Bn)), 72.3 (C-2A), 72.0 (C-5B, C-2C), 71.7 (C-5D), 69.6 (C-3D), 67.4, 66.8 (C-6B, C-6D), 60.0 (C-6A, C-6C), 55.6 (Me (OMP)), 52.9 (C-2D), 51.9 (C-2B); ESI MS: *m/z*: calcd for C₄₉H₆₂N₂O₃₄S₄Na₂²⁻: 698.1; found: 697.7 [*M* + 2Na]²⁻.

4-Methoxyphenyl O-(2-acetamido-2-deoxy-4,6-di-O-sulfo-β-D-galactopyranosyl)-(1 → 4)-O-(β-D-glucopyranosyl)-(1 → 3)-O-(2-acetamido-2-deoxy-4,6-di-O-sulfo-β-D-galactopyranosyl)-(1 → 4)-β-D-glucopyranoside (1). A solution of **3** (12.8 mg, 8.8 μmol, sodium salt) in H₂O/MeOH (4.5 mL/0.5 mL) was hydrogenated

in the presence of 20% Pd(OH)₂/C (25 mg). After 24 h, the suspension was filtered over Celite, concentrated and lyophilised to give **1** as a white amorphous solid (sodium salt; 11.0 mg, 98%). ¹H-NMR (400 MHz, D₂O): δ 7.12 (m, 2H, Ar), 7.00 (m, 2H, Ar), 5.07 (d, 1H, *J*_{1,2} = 8.0 Hz, H-1A), 4.95 (br s, 1H, H-4B), 4.74 (d, 1H, *J*_{3,4} = 2.9 Hz, H-4D), 4.69 (d, 1H, *J*_{1,2} = 8.2 Hz, H-1B), 4.63 (d, 1H, *J*_{1,2} = 8.0 Hz, H-1D), 4.53 (d, 1H, *J*_{1,2} = 7.9 Hz, H-1C), 4.35–4.24 (m, 4H, H-6aB, H-6aD, H-6bB, H-6bD), 4.18–4.13 (m, 2H, H-5B, H-5D), 4.09 (m, 2H, H-2B, H-3B), 4.01–3.91 (m, 2H, H-2D, H-3D), 3.88–3.79 (m, 6H, H-6aA, H-6aC, Me (OMP), H-3A), 3.73–3.57 (m, 7H, H-6bA, H-6bC, H-3C, H-5A, H-4A, H-4C, H-2A), 3.51 (ddd, 1H, *J*_{4,5} = 9.3 Hz, *J*_{5,6a} = 2.1 Hz, *J*_{5,6b} = 4.4 Hz, H-5C), 3.37 (dd, 1H, *J*_{2,3} = 9.1 Hz, H-2C), 2.09, 2.07 (2s, 6H, NHAc); ¹³C-NMR (100 MHz, D₂O; selected data from HSQC experiment): δ 118.1, 115.0 (Ar), 103.8 (C-1C), 101.9 (C-1D), 101.5 (C-1B), 100.7 (C-1A), 80.6 (C-4C), 80.0 (C-4A), 76.6 (C-3B), 76.2 (C-4B), 75.2 (C-4D), 74.5 (C-3C, C-5A), 74.3 (C-3A), 74.1 (C-5C), 73.1 (C-5B or D), 72.5 (C-2A), 72.2 (C-2C), 72.1 (C-5B or D), 69.7 (C-3D), 68.2, 67.8 (C-6B, C-6D), 60.8, 60.0 (C-6A, C-6C), 55.8 (Me (OMP)), 52.7 (C-2D), 51.8 (C-2B); ESI MS: *m/z*: calcd for C₃₅H₅₀N₂O₃₄S₄Na₃⁻: 1239.1; found: 1238.9 [*M* + 3Na]⁻.

4-Methoxyphenyl O-(2-deoxy-3-O-levulinoyl-4,6-O-di-tert-butylsilylene-2-trifluoroacetamido-β-D-galactopyranosyl)-(1 → 4)-O-(2-O-benzoyl-3-O-benzyl-6-O-pivaloyl-β-D-glucopyranosyl)-(1 → 3)-2-deoxy-4,6-O-di-tert-butylsilylene-2-trifluoroacetamido-β-D-galactopyranoside (17). Donor **13** (246 mg, 0.224 mmol) and acceptor **16** (78 mg, 0.15 mmol) were coevaporated with toluene, concentrated *in vacuo* and dissolved in dry CH₂Cl₂ (3.6 mL) in the presence of freshly activated 4 Å molecular sieves (285 mg). After stirring for 15 min at room temperature, TMSOTf (204 μL of a 0.22 M solution in dry CH₂Cl₂) was added under an argon atmosphere. After 45 min, the reaction mixture was neutralized with Et₃N, filtered, and concentrated to dryness. The residue was purified by column chromatography (CH₂Cl₂–MeOH 40 : 1 → CH₂Cl₂–MeOH 30 : 1) to obtain **17** as amorphous solid (123 mg, 56%) and unreacted **16** (20 mg, 26%). TLC (toluene–acetone 5 : 1) R_f 0.58; [α]_D²⁰ +21° (c 1.0, CHCl₃); ¹H-NMR (400 MHz, CDCl₃): δ 7.91 (m, 2H, Ar), 7.56 (m, 1H, Ar), 7.41 (m, 2H, Ar), 7.32 (d, 1H, *J*_{2,NH} = 9.0 Hz, NH-C), 7.15–7.07 (m, 5H, Ar), 6.92–6.88 (m, 3H, Ar, NH-A), 6.77 (m, 2H, Ar), 5.34 (d, 1H, *J*_{1,2} = 8.3 Hz, H-1A), 5.24 (t, 1H, *J*_{1,2} = *J*_{2,3} = 8.0 Hz, H-2B), 5.17 (d, 1H, *J*_{1,2} = 7.6 Hz, H-1B), 4.88 (d, 1H, CH₂(Bn)), 4.86 (dd, 1H, *J*_{2,3} = 11.0 Hz, *J*_{3,4} = 3.0 Hz, H-3C), 4.64 (d, 1H, *J*_{1,2} = 8.4 Hz, H-1C), 4.62 (d, 1H, CH₂(Bn)), 4.60 (d, 1H, *J*_{3,4} = 2.6 Hz, H-4A), 4.55 (d, 1H, H-4C), 4.47–4.39 (m, 2H, H-2C, H-6aB), 4.31–4.24 (m, 2H, H-3A, H-6bB), 4.17–4.08 (m, 4H, H-6aA, H-6bA, H-6aC, H-6bC), 3.99 (m, 1H, H-2A), 3.83 (t, 1H, H-3B), 3.75 (m, 4H, H-4B, Me (OMP)), 3.62 (m, 1H, H-5B), 3.37 (br s, 1H, H-5A), 3.30 (br s, 1H, H-5C), 2.74 (m, 2H, CH₂(Lev)), 2.58 (m, 2H, CH₂(Lev)), 2.17 (s, 3H, CH₃(Lev)), 1.22 (s, 9H, C(CH₃)₃), 1.07, 1.00 (2s, 36H, Si(C(CH₃)₃)₂); ¹³C-NMR (100 MHz, CDCl₃): δ 206.7, 179.1, 172.7, 165.2 (4 × CO), 157.8 (q, *J*_{C,F} = 37.5 Hz, COCF₃), 157.7 (q, *J*_{C,F} = 36.9 Hz, COCF₃), 156.0–114.6 (Ar), 115.9 (q, *J*_{C,F} = 288.4 Hz, COCF₃), 115.6 (q, *J*_{C,F} = 288.4 Hz, COCF₃), 101.7 (C-1C), 100.0 (C-1B), 99.4 (C-1A),



80.7 (C-3B), 78.7 (C-4B), 75.0 (C-3A), 74.4 (CH₂(Bn)), 74.1 (C-5B), 73.2 (C-2B, C-4A), 72.8 (C-3C), 71.9 (C-5C), 71.6 (C-5A), 69.5 (C-4C), 67.1 (C-6A), 66.7 (C-6C), 63.2 (C-6B), 55.7 (Me (OMP)), 53.9 (C-2A), 51.0 (C-2C), 39.1 (C(CH₃)₃), 38.0 (CH₂(Lev)), 29.8 (CH₃(Lev)), 28.3 (CH₂(Lev)), 27.7, 27.6, 27.4, 27.3 (Si(C(CH₃)₃)₂, C(CH₃)₃), 23.4, 20.9, 20.6 (Si(C(CH₃)₃)₂); HR MS: *m/z*: calcd for C₆₉H₉₄F₆N₂O₂₁Si₂Na: 1479.5690; found: 1479.5671 [M + Na]⁺.

4-Methoxyphenyl O-(2-deoxy-4,6-O-di-*tert*-butylsilylene-2-trifluoroacetamido-β-D-galactopyranosyl)-(1 → 4)-O-(2-O-benzoyl-3-O-benzyl-6-O-pivaloyl-β-D-glucopyranosyl)-(1 → 3)-2-deoxy-4,6-O-di-*tert*-butylsilylene-2-trifluoroacetamido-β-D-galactopyranoside (18). Compound 17 (190 mg, 0.130 mmol) was dissolved in CH₂Cl₂ (3.5 mL) and hydrazine monohydrate (0.52 mL of a 0.5 M solution in Py/AcOH 3 : 2) was added. After stirring at room temperature for 2 h, the reaction mixture was quenched with acetone (0.8 mL). The mixture was diluted with CH₂Cl₂ and washed with 1 M HCl aqueous solution, saturated NaHCO₃ aqueous solution and H₂O. The organic layer was dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was purified by column chromatography (toluene–acetone 9 : 1) to afford 18 (168 mg, 95%) as a white amorphous solid. TLC (toluene–acetone 9 : 1) R_f 0.15; [α]_D²⁰ +10° (c 1.0, CHCl₃); ¹H-NMR (400 MHz, CDCl₃): δ 7.89 (m, 2H, Ar), 7.56 (m, 1H, Ar), 7.40 (m, 2H, Ar), 7.32 (d, 1H, J_{2,NH} = 9.2 Hz, NH-C), 7.15–7.04 (m, 5H, Ar), 6.90 (m, 2H, Ar), 6.83 (d, 1H, J_{2,NH} = 6.9 Hz, NH-A), 6.77 (m, 2H, Ar), 5.35 (d, 1H, J_{1,2} = 8.2 Hz, H-1A), 5.23 (t, 1H, J_{1,2} = J_{2,3} = 8.1 Hz, H-2B), 5.18 (d, 1H, J_{1,2} = 7.8 Hz, H-1B), 4.92 (d, 1H, CH₂(Bn)), 4.59 (m, 2H, H-4A, CH₂(Bn)), 4.45–4.33 (m, 4H, H-6aB, H-1C, H-4C, H-6bB), 4.31 (dd, 1H, J_{2,3} = 11.2 Hz, J_{3,4} = 2.6 Hz, H-3A), 4.26–4.13 (m, 5H, H-6aC, H-2C, H-6aA, H-6bA, H-6bC), 3.98 (m, 1H, H-2A), 3.80 (t, 1H, J_{3,4} = 8.2 Hz, H-3B), 3.75 (s, 3H, Me (OMP)), 3.70 (t, 1H, J_{4,5} = 7.9 Hz, H-4B), 3.63–3.57 (m, 2H, H-5B, H-3C), 3.38 (br s, 1H, H-5A), 3.32 (br s, 1H, H-5C), 2.79 (d, 1H, J_{3,OH} = 11.6 Hz, OH), 1.23 (s, 9H, C(CH₃)₃), 1.07, 1.04, 1.01 (4s, 36H, Si(C(CH₃)₃)₂); ¹³C-NMR (100 MHz, CDCl₃): δ 179.4, 165.2 (2 × CO), 158.3 (q, J_{C,F} = 37.4 Hz, COCF₃), 157.7 (q, J_{C,F} = 36.9 Hz, COCF₃), 156.0–114.6 (Ar), 116.03 (q, J_{C,F} = 288.6 Hz, COCF₃), 115.6 (q, J_{C,F} = 289.1 Hz, COCF₃), 102.2 (C-1C), 100.0 (C-1B), 99.3 (C-1A), 80.7 (C-3B), 79.2 (C-4B), 75.1 (C-3A), 75.0 (CH₂(Bn)), 74.2 (C-5B), 73.3 (C-4A), 73.1 (C-2B), 72.3 (C-5C), 71.9 (C-3C), 71.8 (C-4C), 71.6 (C-5A), 67.1 (C-6A), 66.5 (C-6C), 62.8 (C-6B), 55.7 (Me (OMP)), 54.0 (C-2A), 53.9 (C-2C), 39.2 (C(CH₃)₃), 27.7, 27.6, 27.4, 27.3 (Si(C(CH₃)₃)₂, C(CH₃)₃), 23.5, 23.4, 20.9, 20.7 (Si(C(CH₃)₃)₂); HR MS: *m/z*: calcd for C₆₄H₈₈F₆N₂O₁₉Si₂Na: 1381.5322; found: 1381.5305 [M + Na]⁺.

4-Methoxyphenyl O-(2-deoxy-3-O-levulinoyl-4,6-O-di-*tert*-butylsilylene-2-trifluoroacetamido-β-D-galactopyranosyl)-(1 → 4)-O-(2-O-benzoyl-3-O-benzyl-6-O-pivaloyl-β-D-glucopyranosyl)-(1 → 3)-O-(2-deoxy-4,6-O-di-*tert*-butylsilylene-2-trifluoroacetamido-β-D-galactopyranosyl)-(1 → 4)-O-(2-O-benzoyl-3-O-benzyl-6-O-pivaloyl-β-D-glucopyranosyl)-(1 → 3)-2-deoxy-4,6-O-di-*tert*-butylsilylene-2-trifluoroacetamido-β-D-galactopyranoside (19). Donor 13 (223 mg, 0.203 mmol) and acceptor 18 (92 mg, 0.068 mmol) were coevaporated with toluene, concen-

trated *in vacuo* and dissolved in dry CH₂Cl₂ (3.0 mL) in the presence of freshly activated 4 Å molecular sieves (225 mg). After stirring for 15 min at room temperature, TBSOTf (239 μL of a 0.17 M solution in dry CH₂Cl₂) was added under an argon atmosphere. After 40 min, the reaction mixture was neutralized with Et₃N, filtered, and concentrated to dryness. The residue was purified by column chromatography (CH₂Cl₂–acetone 40 : 1 → CH₂Cl₂–acetone 30 : 1) to obtain 19 as a white amorphous solid (81 mg, 52%), and unreacted 18 (22 mg, 24%). TLC (toluene–acetone 9 : 1) R_f 0.31; [α]_D²⁰ +25° (c 1.0, CHCl₃); ¹H-NMR (400 MHz, CDCl₃): δ 7.92 (m, 4H, Ar), 7.54 (m, 2H, Ar), 7.39 (m, 4H, Ar), 7.22 (m, 2H, NH), 7.15–7.06 (m, 10H, Ar), 7.00 (d, 1H, J_{2,NH} = 7.2 Hz, NH), 6.91 (m, 2H, Ar), 6.77 (m, 2H, Ar), 5.34 (d, 1H, J_{1,2} = 8.3 Hz, H-1A), 5.21 (m, 2H, H-1B or D, H-2B or D), 5.16 (t, 1H, J_{1,2} = J_{2,3} = 7.5 Hz, H-2B or D), 4.99 (d, 1H, J_{1,2} = 7.4 Hz, H-1B or D), 4.89–4.82 (m, 3H, H-1C, H-3E, CH₂(Bn)), 4.80 (d, 1H, CH₂(Bn)), 4.64–4.59 (m, 4H, CH₂(Bn), H-1E, H-4A), 4.54 (br s, 1H, H-4E), 4.52 (m, 1H, H-6aB or D), 4.49 (br s, 1H, H-4C), 4.45–4.37 (m, 2H, H-2E, H-6aB or D), 4.31 (dd, 1H, J_{5,6} = 4.8 Hz, J_{6a,6b} = 12.1 Hz, H-6bB or D), 4.25 (dd, 1H, J_{2,3} = 11.3 Hz, J_{3,4} = 2.5 Hz, H-3A), 4.17–4.13 (m, 3H, H-6aA, H-6bA, H-6aE), 4.09–4.03 (m, 2H, H-6bE, H-6bB or D), 4.01–3.95 (m, 5H, H-2A, H-2C, H-3C, H-6aC, H-6bC), 3.83–3.79 (m, 2H, H-3B, H-3D), 3.76–3.71 (m, 5H, Me (OMP), H-4B, H-4D), 3.64–3.57 (m, 2H, H-5B, H-5D), 3.35 (br s, 1H, H-5A), 3.28 (br s, 1H, H-5E), 3.07 (br s, 1H, H-5C), 2.75 (m, 2H, CH₂(Lev)), 2.59 (m, 2H, CH₂(Lev)), 2.17 (s, 3H, CH₃(Lev)), 1.20, 1.18 (2s, 18H, C(CH₃)₃), 1.06, 1.00, 0.98, 0.96, 0.95, 0.93 (6s, 54H, Si(C(CH₃)₃)₂); ¹³C-NMR (100 MHz, CDCl₃): δ 206.6, 179.0, 178.5, 172.7, 165.3, 165.2 (6 × CO), 157.9 (q, J_{C,F} = 36.9 Hz, COCF₃), 157.8 (q, J_{C,F} = 36.9 Hz, COCF₃), 157.7 (q, J_{C,F} = 36.9 Hz, COCF₃), 155.9–114.5 (Ar), 115.9 (q, J_{C,F} = 288.1 Hz, COCF₃), 115.7 (q, J_{C,F} = 288.6 Hz, COCF₃), 115.6 (q, J_{C,F} = 288.6 Hz, COCF₃), 101.6 (C-1E), 100.6 (C-1C), 100.1, 99.5 (C-1B, C-1D), 99.4 (C-1A), 81.1, 80.6 (C-3B, C-3D), 78.1, 78.0 (C-4B, C-4D), 75.4 (C-3C), 74.8 (C-3A), 74.5, 74.4 (C-5B, C-5D), 74.2, 73.7 (2 × CH₂(Bn)), 73.4 (C-2B), 73.3, 73.2 (C-2D, C-4A), 72.8 (C-3E), 72.4 (C-4C), 71.9 (C-5E, C-5C), 71.6 (C-5A), 69.5 (C-4E), 67.1 (C-6A), 66.8, 66.6 (C-6C, C-6E), 63.6, 62.9 (C-6B, C-6D), 55.7 (Me (OMP)), 53.8, 53.3 (C-2A, C-2C), 51.0 (C-2E), 39.1, 39.0 (C(CH₃)₃), 38.0 (CH₂(Lev)), 29.8 (CH₃(Lev)), 28.3 (CH₂(Lev)), 27.7, 27.6, 27.5, 27.4, 27.3 (Si(C(CH₃)₃)₂, C(CH₃)₃), 23.4, 23.3, 20.9, 20.6 (Si(C(CH₃)₃)₂); ¹⁹F NMR (376 MHz, CDCl₃): δ –75.5 (s, 3F), –75.8 (s, 3F), –76.0 (s, 3F); HR MS: *m/z*: calcd for C₁₁₀H₁₄₈F₉N₃O₃₃Si₃Na: 2316.9062; found: 2316.9160 [M + Na]⁺.

4-Methoxyphenyl O-(2-deoxy-3-O-levulinoyl-2-trifluoroacetamido-β-D-galactopyranosyl)-(1 → 4)-O-(2-O-benzoyl-3-O-benzyl-6-O-pivaloyl-β-D-glucopyranosyl)-(1 → 3)-O-(2-deoxy-2-trifluoroacetamido-β-D-galactopyranosyl)-(1 → 4)-O-(2-O-benzoyl-3-O-benzyl-6-O-pivaloyl-β-D-glucopyranosyl)-(1 → 3)-2-deoxy-2-trifluoroacetamido-β-D-galactopyranoside (20). An excess of (HF)_nPy (152 μL, 5.8 mmol) was added at 0 °C under an argon atmosphere to a solution of 19 (67 mg, 0.029 mmol) in dry THF (3.0 mL). After 16 h at 0 °C the mixture was diluted with CH₂Cl₂ and washed with H₂O, saturated NaHCO₃ solution and H₂O. The organic layers were dried (MgSO₄), filtered and con-



concentrated *in vacuo* to give **20** (53 mg, 97%) as a white amorphous solid. TLC (toluene–acetone 1 : 1) Rf 0.32; ¹H-NMR (400 MHz, CDCl₃/CD₃OD 4 : 1): δ 7.93 (m, 4H, Ar), 7.59 (m, 2H, Ar), 7.43 (m, 4H, Ar), 7.12–6.99 (m, 10H, Ar), 6.85 (m, 2H, Ar), 6.71 (m, 2H, Ar), 5.07–5.00 (m, 2H, H-2B, H-2D), 4.99 (d, 1H, *J*_{1,2} = 8.5 Hz, H-1A), 4.97, 4.91 (2d, 2H, CH₂(Bn)), 4.86 (dd, 1H, *J*_{2,3} = 11.1 Hz, *J*_{3,4} = 3.2 Hz, H-3E), 4.71 (d, 1H, *J*_{1,2} = 7.9 Hz, H-1B or D), 4.66 (d, 1H, *J*_{1,2} = 7.9 Hz, H-1B or D), 4.53–4.46 (m, 5H, H-1C, H-1E, CH₂(Bn), H-6aB, H-6aD), 4.43–4.38 (m, 2H, H-2E, CH₂(Bn)), 4.13 (dd, 1H, *J*_{2,3} = 11.1 Hz, *J*_{3,4} = 2.9 Hz, H-3A), 4.04 (d, 1H, H-4A), 4.03–3.94 (m, 4H, H-2C, H-4E, H-4C, H-6bB or D), 3.94–3.76 (m, 8H, H-4B, H-4D, H-2A, H-6bB or D, H-3C, H-3B or D, H-6aA or C or E), 3.74–3.68 (m, 6H, H-3B or D, H-6aA or C or E, H-6bA or C or E, Me (OMP)), 3.59 (ddd, 1H, *J*_{4,5} = 9.5 Hz, *J*_{5,6} = 1.9 and 5.7 Hz, H-5B or D), 3.55–3.44 (m, 5H, H-5A, H-5C, H-5E, H-6bA or C or E), 2.84–2.45 (m, 4H, CH₂(Lev)), 2.15 (s, 3H, CH₃(Lev)), 1.20, 1.17 (2s, 18H, C(CH₃)₃); ¹³C-NMR (100 MHz, CDCl₃/CD₃OD 4 : 1): δ 208.7, 179.3, 179.2, 172.7, 166.0, 165.9 (6 × CO), 158.4 (m, 3 × COCF₃), 155.7–114.7 (Ar), 116.3 (q, *J*_{C,F} = 287.5 Hz, COCF₃), 115.9 (q, *J*_{C,F} = 287.5 Hz, COCF₃), 115.8 (q, *J*_{C,F} = 287.5 Hz, COCF₃), 101.3 (C-1B, C-1D), 100.5, 100.1 (C-1C, C-1E), 99.8 (C-1A), 80.7, 80.6 (C-3B, C-3D), 79.0 (C-3C), 78.2 (C-3A), 76.9, 76.8, 76.7 (2 × CH₂(Bn), C-5B or D, C-5A or C or E), 75.2, 75.1 (C-5A or C or E, C-4B or D), 74.3 (C-4B or D), 73.8, 73.7 (C-5B or D, C-5A or C or E), 73.2 (C-3E), 73.0 (C-2B, C-2D), 68.2 (C-4A, C-4C), 66.3 (C-4E), 62.5, 62.2, 61.8, 61.6 (C-6A, C-6B, C-6C, C-6D, C-6E), 55.8 (Me (OMP)), 52.9 (C-2A), 52.7 (C-2C), 51.3 (C-2E), 39.2 (C(CH₃)₃), 38.1 (CH₂(Lev)), 29.7 (CH₃(Lev)), 28.1 (CH₂(Lev)), 27.1 (C(CH₃)₃); HR MS: *m/z*: calcd for C₈₆H₁₀₀F₉N₃O₃₃Na: 1896.5988; found: 1896.5979 [*M* + Na]⁺.

4-Methoxyphenyl O-(2-deoxy-3-O-levulinoyl-4,6-di-O-sulfo-2-trifluoroacetamido-β-D-galactopyranosyl)-(1 → 4)-O-(2-O-benzoyl-3-O-benzyl-6-O-pivaloyl-β-D-glucopyranosyl)-(1 → 3)-O-(2-deoxy-4,6-di-O-sulfo-2-trifluoroacetamido-β-D-galactopyranosyl)-(1 → 4)-O-(2-O-benzoyl-3-O-benzyl-6-O-pivaloyl-β-D-glucopyranosyl)-(1 → 3)-2-deoxy-4,6-di-O-sulfo-2-trifluoroacetamido-β-D-galactopyranoside (6). Compound **20** (53 mg, 28 μmol) and sulfur trioxide–trimethylamine complex (236 mg, 1.7 mmol) were dissolved in dry DMF (5.0 mL) and heated at 100 °C for 30 min using microwave radiation (40 W average power). The reaction vessel was cooled and Et₃N (400 μL), MeOH (2.0 mL) and CH₂Cl₂ (2.0 mL) were added. The solution was first purified by Sephadex LH 20 chromatography (CH₂Cl₂–MeOH 1 : 1). The residue was then purified by silica gel column chromatography (EtOAc–MeOH–H₂O 20 : 5 : 3 → EtOAc–MeOH–H₂O 16 : 5 : 3) and finally eluted from a Dowex 50WX2-Na⁺ column (MeOH) to obtain **6** as sodium salt (55 mg, 78%, white amorphous solid). TLC (EtOAc–MeOH–H₂O 16 : 5 : 3) Rf 0.29; ¹H-NMR (400 MHz, CD₃OD): δ 7.95 (m, 4H, Ar), 7.62 (m, 2H, Ar), 7.45 (m, 4H, Ar), 7.16–6.97 (m, 10H, Ar), 6.96 (m, 2H, Ar), 6.80 (m, 2H, Ar), 5.23 (m, 2H, H-2B, H-2D), 5.05 (dd, 1H, *J*_{2,3} = 11.3 Hz, *J*_{3,4} = 3.2 Hz, H-3E), 4.99, 4.95 (2d, 2H, CH₂(Bn)), 4.89 (m, 2H, H-4E, H-4A or C), 4.87 (d, 1H, *J*_{3,4} = 3.0 Hz, H-4A or C), 4.80–4.73 (m, 4H, H-1A, H-1B, H-1D, H-1E), 4.64 (d, 1H, *J*_{1,2} = 8.2 Hz, H-1C), 4.55, 4.52 (2d, 2H, CH₂(Bn)), 4.44–4.29 (m, 7H,

H-6aA, H-6aB, H-6aC, H-6aD, H-6aE, H-2E, H-6bA or C or E), 4.27–4.08 (m, 6H, H-2A, H-6bB, H-6bD, H-2C, H-6bA or C or E), 4.07–3.97 (m, 6H, H-4B, H-4D, H-3A, H-3C, H-5A or C or E), 3.92–3.83 (m, 3H, H-3B, H-3D, H-5A or C or E), 3.78–3.69 (m, 5H, H-5B, H-5D, Me (OMP)), 2.80 (m, 2H, CH₂(Lev)), 2.59 (m, 2H, CH₂(Lev)), 2.13 (s, 3H, CH₃(Lev)), 1.26 (2s, 18H, C(CH₃)₃); ¹³C-NMR (100 MHz, CD₃OD): δ 209.7, 180.1, 180.0, 173.9, 167.6 (6 × CO), 159.4 (q, *J*_{C,F} = 37.1 Hz, COCF₃), 159.3 (q, *J*_{C,F} = 37.3 Hz, COCF₃), 159.2 (q, *J*_{C,F} = 37.0 Hz, COCF₃), 156.9–115.5 (Ar), 117.4 (q, *J*_{C,F} = 286.8 Hz, COCF₃), 117.2 (q, *J*_{C,F} = 287.3 Hz, 2 × COCF₃), 102.6, 102.5 (C-1B, C-1D), 102.3 (C-1A), 101.2 (C-1E), 101.0 (C-1C), 81.1, 80.8 (C-3B, C-3D), 77.8, 77.2 (C-4B, C-4D), 76.9 (C-3A or C), 76.8 (C-4A, C-4C), 76.3 (C-3A or C), 76.1, 75.5 (2 × CH₂(Bn)), 75.0, 74.9 (C-5B, C-5D), 74.8, 74.7, 74.6, 74.5 (C-2B, C-2D, C-5A or C or E), 74.0 (C-5A or C or E), 72.4 (C-4E), 71.9 (C-3E), 68.9, 68.3, 67.8 (C-6A, C-6C, C-6E), 64.4, 64.2 (C-6B, C-6D), 56.0 (Me (OMP)), 54.0 (C-2C), 53.3 (C-2A), 52.5 (C-2E), 40.0 (C(CH₃)₃), 38.5 (CH₂(Lev)), 29.6 (CH₃(Lev)), 29.2 (CH₂(Lev)), 27.8 (C(CH₃)₃); ¹⁹F NMR (376 MHz, CD₃OD): δ –76.5 (s, 3F), –76.9 (s, 3F), –77.1 (s, 3F); ESI MS: *m/z*: calcd for C₈₆H₉₄F₉N₃O₅₁S₆Na₄²⁻: 1219.6; found: 1219.2 [*M* + 4Na]²⁻.

4-Methoxyphenyl O-(2-acetamido-2-deoxy-4,6-di-O-sulfo-β-D-galactopyranosyl)-(1 → 4)-O-(3-O-benzyl-β-D-glucopyranosyl)-(1 → 3)-O-(2-acetamido-2-deoxy-4,6-di-O-sulfo-β-D-galactopyranosyl)-(1 → 4)-O-(3-O-benzyl-β-D-glucopyranosyl)-(1 → 3)-2-acetamido-2-deoxy-4,6-di-O-sulfo-β-D-galactopyranoside (4). H₂O₂ (30%, 336 μL) and an aqueous solution of LiOH (0.7 M, 205 μL) were added at 0 °C to a solution of **6** (21 mg, 8.4 μmol) in MeOH (1.2 mL). After stirring for 24 h at room temperature, MeOH (1.5 mL), an aqueous solution of NaOH (4 M, 420 μL) and H₂O (0.5 mL) were added. After stirring for 72 h at room temperature, the reaction mixture was neutralized with Amberlite IR-120 (H⁺) resin, filtered, and concentrated to give the desired diamine intermediate. Triethylamine (47 μL, 0.33 mmol) and acetic anhydride (48 μL, 0.51 mmol) were added to a cooled (0 °C) solution of this diamine derivative in MeOH (2.2 mL). Three additional portions of triethylamine (0.33 mmol each) and acetic anhydride (0.51 mmol each) were added every 2 hours in order to complete the reaction. After stirring for 8 h at room temperature, Et₃N (300 μL) was added and the mixture was concentrated to dryness. The residue was purified by Sephadex LH 20 chromatography column which was eluted with H₂O–MeOH (9 : 1) to obtain **4**. This compound was then dissolved in H₂O (2 mL) and Amberlite IR-120 H⁺ resin was added (pH 3.0). The mixture was immediately filtered, treated with 0.04 M NaOH (pH 7.1) and eluted from a column of Dowex 50WX4-Na⁺ (H₂O) to obtain **4** as sodium salt (14 mg, 89%) after lyophilization. TLC (EtOAc–MeOH–H₂O 10 : 5 : 3) Rf 0.14; ¹H-NMR (400 MHz, D₂O): δ 7.58–7.38 (m, 10H, Ar), 7.12 (m, 2H, Ar), 7.00 (m, 2H, Ar), 5.08 (d, 1H, *J*_{1,2} = 8.6 Hz, H-1A), 5.01–4.97 (m, 3H, H-4A, CH₂(Bn)), 4.93 (d, 1H, *J*_{3,4} = 2.7 Hz, H-4C), 4.88–4.82 (m, 2H, CH₂(Bn)), 4.76–4.73 (m, 2H, H-4E, H-1C), 4.64 (d, 1H, *J*_{1,2} = 8.3 Hz, H-1E), 4.55, 4.52 (2d, 2H, *J*_{1,2} = 7.8 Hz, H-1B, H-1D), 4.39–4.19 (m, 6H, H-2A, H-6aA, H-6aC, H-6aE, H-6bA or C or E, H-5A or C or E),



4.16–3.88 (m, 13H, H-3A, H-2C, H-6bA or C or E, H-2E, H-3C, H-5A or C or E, H-3E, H-4B, H-4D, H-6aB, H-6aD), 3.83 (s, 3H, Me (OMP)), 3.76–3.65 (m, 4H, H-6bB, H-6bD, H-3B, H-3D), 3.60–3.46 (m, 4H, H-2B, H-2D, H-5B, H-5D), 2.07, 2.06, 2.05 (3s, 9H, NHAc); ^{13}C -NMR (100 MHz, D_2O ; selected data from HSQC experiment): δ 104.0 (C-1B, C-1D), 100.6 (C-1E), 100.4 (C-1A), 100.1 (C-1C), 81.4 (C-3B, C-3D), 76.5 (C-3C), 76.4 (C-3A), 76.2 (C-4C), 76.0 (C-4A), 75.2 (C-4E), 75.0 (C-4B, C-4D), 74.7 (C-5B, C-5D), 73.4 ($2 \times \text{CH}_2(\text{Bn})$), 72.4 (C-5A or C or E), 72.1 (C-2B, C-2D), 71.8 (C-5A or C or E), 69.6 (C-3E), 67.5, 67.1, 66.8 (C-6A, C-6C, C-6E), 60.0 (C-6B, C-6D), 55.6 (Me (OMP)), 52.9 (C-2E), 51.8 (C-2C), 51.3 (C-2A); ESI MS: m/z : calcd for $\text{C}_{57}\text{H}_{73}\text{N}_3\text{O}_{45}\text{S}_6\text{Na}_4^{2-}$: 901.6; found: 901.1 $[M + 4\text{Na}]^{2-}$.

4-Methoxyphenyl O-(2-acetamido-2-deoxy-4,6-di-O-sulfo- β -D-galactopyranosyl)-(1 \rightarrow 4)-O-(β -D-glucopyranosyl)-(1 \rightarrow 3)-O-(2-acetamido-2-deoxy-4,6-di-O-sulfo- β -D-galactopyranosyl)-(1 \rightarrow 4)-O-(β -D-glucopyranosyl)-(1 \rightarrow 3)-2-acetamido-2-deoxy-4,6-di-O-sulfo- β -D-galactopyranoside (2). A solution of **4** (7.1 mg, 3.9 μmol , sodium salt) in $\text{H}_2\text{O}/\text{MeOH}$ (4.5 mL/0.5 mL) was hydrogenated in the presence of 20% $\text{Pd}(\text{OH})_2/\text{C}$ (14 mg). After 24 h, the suspension was filtered over Celite, concentrated and lyophilised to give **2** as a white amorphous solid (sodium salt; 6.5 mg, quantitative). ^1H -NMR (400 MHz, D_2O): δ 7.11 (m, 2H, Ar), 6.99 (m, 2H, Ar), 5.07 (d, 1H, $J_{1,2} = 8.5$ Hz, H-1A), 4.98 (d, 1H, $J_{3,4} = 3.0$ Hz, H-4A), 4.94 (br s, 1H, H-4C), 4.74 (d, 1H, $J_{3,4} = 2.7$ Hz, H-4E), 4.67 (d, 1H, $J_{1,2} = 8.0$ Hz, H-1C), 4.62 (d, 1H, $J_{1,2} = 7.9$ Hz, H-1E), 4.54 (m, 2H, H-1B, H-1D), 4.38–4.23 (m, 8H, H-2A, H-6aA, H-6aC, H-6aE, H-6bA, H-6bC, H-6bE, H-5A or C or E), 4.17–4.06 (m, 5 H, H-5A or C or E, H-3A, H-3C, H-2C), 4.00–3.91 (m, 2H, H-2E, H-3E), 3.86–3.81 (m, 5H, H-6aB, H-6aD, Me (OMP)), 3.70–3.59 (m, 6H, H-3B, H-3D, H-6bB, H-6bD, H-4B, H-4D), 3.54–3.48 (m, 2H, H-5B, H-5D), 3.42–3.34 (m, 2H, H-2B, H-2D), 2.09, 2.07, 2.04 (3s, 9H, NHAc); ^{13}C -NMR (100 MHz, D_2O ; selected data from HSQC experiment): δ 103.6 (C-1B, C-1D), 101.8 (C-1E), 101.4 (C-1C), 100.5 (C-1A), 80.1 (C-4B, C-4D), 76.2 (C-3A, C-3C), 76.0 (C-4A), 75.9 (C-4C), 74.9 (C-4E), 74.0 (C-3B, C-3D), 73.8 (C-5B, C-5D), 72.3, 72.2 (C-5A, C-5C, C-5E), 72.0 (C-2B, C-2D), 69.4 (C-3E), 67.5 (C-6A, C-6C, C-6E), 60.0 (C-6B, C-6D), 55.6 (Me (OMP)), 52.4 (C-2E), 51.4 (C-2C), 51.3 (C-2A); ESI MS: m/z : calcd for $\text{C}_{43}\text{H}_{61}\text{N}_3\text{O}_{45}\text{S}_6\text{Na}_4^{2-}$: 811.5; found: 811.2 $[M + 4\text{Na}]^{2-}$.

FP assays

FP measurements were performed in 384-well microplates (black polystyrene, non-treated, Corning). FP was recorded using a TRIAD multimode microplate reader (from Dynex), with excitation and emission wavelengths of 485 and 535 nm, respectively. The fluorescent probe (a fluorescein labelled heparin-like hexasaccharide previously prepared in our lab)³⁵ was dissolved in PBS buffer (10 mM, pH 7.4). Recombinant human midkine (Peprotech) was dissolved in PBS buffer (10 mM, pH 7.4) containing 1% BSA (bovine serum albumin). Compounds **1–4** were dissolved in PBS buffer (10 mM, pH 7.4). 1 mM stock solutions of compounds **5** and **6** were prepared in PBS/DMSO 9 : 1 (v/v) and serial dilutions were then performed in PBS buffer (10 mM, pH 7.4).

For the determination of the IC_{50} values, we recorded the FP from wells containing 20 μL of a 125 nM midkine solution and 10 μL of a 40 nM probe solution in the presence of 10 μL of inhibitor solution, with concentrations ranging from 2 mM to 0.1 μM . The microplate was shaken in the dark for 5 min, before reading. The total sample volume in each well was 40 μL and the final buffer composition was PBS + 0.5% BSA. The final concentrations of fluorescent probe and midkine in each well were 10 nM and 63 nM, respectively, while the final inhibitor concentration ranged from 500 μM to 25 nM. The average polarization values of three replicates were plotted against the logarithm of inhibitor concentration. Two control samples were included in the competition experiment. The first one only contained fluorescent probe and afforded the expected minimum polarization value for 100% inhibition; the second one contained midkine and probe, in the absence of inhibitor, and gave the maximum polarization value corresponding to 0% inhibition. Blank wells contained 20 μL of protein solution and 20 μL of a 125 μM inhibitor solution and their measurements were subtracted from all values. The resulting curve was fitted to the equation for a one-site competition: $y = A_2 + (A_1 - A_2)/[1 + 10^{(x - \log \text{IC}_{50})}]$ where A_1 and A_2 are the maximal and minimal values of polarization, respectively, and IC_{50} is the inhibitor concentration that results in 50% inhibition. At least two independent experiments were carried out for each IC_{50} calculation.

Nuclear magnetic resonance

Experiments were performed in a Bruker Avance III 700 MHz fitted with a QCI 5 mm cryoprobe for ^1H , ^{13}C , ^{15}N , ^{31}P with cold preamplifiers in ^1H , ^{13}C and ^2H channels or in 600 MHz Avance III fitted with a QCI 5 mm cryoprobe for ^1H , ^{13}C , ^{15}N , ^{19}F with cold preamplifiers in ^1H , ^{19}F , ^{13}C and ^2H channels, at 298 K. STD-NMR samples were prepared in 300 μL of 99.9% D_2O buffer containing 10 mM phosphate pD 7.5 and 150 mM NaCl. Ligand and midkine concentrations were 1.0 mM and 20 μM , respectively. NMR pulse sequences from the manufacturer library were used for the assignment.

STD NMR experiments were carried out with watergate solvent suppression and a 10 ms spin-lock filter after the 90° pulse to reduce residual signals from the protein. For selective protein saturation, cascades of 50 ms Gaussian shaped pulses at a field strength of *circa* 50 Hz were employed, with a delay of 1 ms between successive pulses.⁴⁵ The on-resonance and off-resonance frequencies were set to 1.7 ppm and 40 ppm, respectively. Blank experiments were performed to assure the absence of direct saturation of the ligand proton signals. The relaxation delay was properly adjusted so that the experiment time length was kept constant (5.0 s). STD NMR experiments were performed with 512–256 scans. Saturation times were of 1, 1.5, 2.0, 3.0, 4.0 and 5.0 s.

To avoid relaxation interference in STD, STD_0 were calculated from the STD initial slopes.^{48,49} To do so, the evolution of the STD with the saturation time (t_{sat}) was fitted to the equation $\text{STD}(t) = a(1 - \exp(-bt))$, where the parameter a represents the asymptotic maximum of the STD build-up curve



(STD_{max}), b is a rate constant related to the relaxation properties of a given proton that measures the speed of the STD build-up (k_{sat}), and t is the saturation time (t_{sat}). Thus, the STD_0 values were obtained as the product of the ab coefficients.

Molecular dynamics (MD)

All starting structures were constructed with MAESTRO suite (Schrödinger, LLC, New York, NY, 2019). Partial charges were obtained from GLYCAM⁵⁰ or derived from the molecular electrostatic potential, MEP, using the RESP method.⁵¹ The procedure has been developed under GLYCAM06 force fields available in the R.E.D web server. The partial charges for SO_3 groups were established according to the protocol of GLYCAM.

The prep and frcmod files were obtained by antechamber and parmchk modules in AmberTools using each residue of each sugar and the set of partial charges. By means of AMBER 12 version, the topology and coordinates initials were built with tLEAP module, where both tetrasaccharides and pentasaccharides were neutralized with sodium ions and immersed in a TIP3P water box as explicit solvent.⁵² This procedure was carried out using GLYCAM06 as force files and parm99 parameters.

To achieve system equilibrium, we followed a protocol that consisted in several steps. Firstly, an initial energy minimization of the solute in the water box was performed followed by a minimization of the entire system, including sodium ions. Next, the system was heated from 0 K to 300 K at a constant volume, and then equilibrated at a constant pressure (1 bar). At this point, the final step was the production dynamics simulations, with an overall length from 200 to 500 ns. The coordinates of the trajectories were saved each picosecond. We run the first steps of simulations with sander.MPI and the final production with pmemd.MPI extension, belonging to AMBER program.

For those mimetics that presented some distortions in their conformations, we carried out time-average distance restrained MD (MD-tar) simulations. This procedure has a shorter length (8–50 ns). NOE-derived distances between H_1-H_3 , H_1-H_5 and H_3-H_5 protons were employed as restraints. The trajectories of all simulations were analyzed with *cpptraj* module of Amber12. All protocols have been described in detail in the ESI.†

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We thank the Spanish Ministry of Economy and Competitiveness and the Spanish Ministry of Science and Innovation (CTQ2015-70134-P, PGC2018-099497-B100), Junta de Andalucía (P12-BIO-1938) and the European Union (ERDF)

for financial support. 700 MHz NMR experiments have been performed in the NMR service of the US (CITIUS).

Notes and references

- 1 S. Mizumoto, S. Yamada and K. Sugahara, *Curr. Opin. Struct. Biol.*, 2015, **34**, 35–42.
- 2 K. Sugahara, T. Mikami, T. Uyama, S. Mizuguchi, K. Nomura and H. Kitagawa, *Curr. Opin. Struct. Biol.*, 2003, **13**, 612–620.
- 3 C. I. Gama, S. E. Tully, N. Sotogaku, P. M. Clark, M. Rawat, N. Vaidehi, W. A. Goddard, A. Nishi and L. C. Hsieh-Wilson, *Nat. Chem. Biol.*, 2006, **2**, 467–473.
- 4 C. J. Rogers, P. M. Clark, S. E. Tully, R. Abrol, K. C. Garcia, W. A. Goddard III and L. C. Hsieh-Wilson, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 9747–9752.
- 5 T. Muramatsu, *Curr. Pharm. Des.*, 2011, **17**, 410–423.
- 6 K. Kadomatsu, S. Kishida and S. Tsubota, *J. Biochem.*, 2013, **153**, 511–521.
- 7 E. Bedini and M. Parrilli, *Carbohydr. Res.*, 2012, **356**, 75–85.
- 8 M. Mende, C. Bednarek, M. Wawryczyn, P. Sauter, M. B. Biskup, U. Schepers and S. Braese, *Chem. Rev.*, 2016, **116**, 8193–8255.
- 9 X. Zhang, H. Liu, W. Yao, X. Meng and Z. Li, *J. Org. Chem.*, 2019, **84**, 7418–7425.
- 10 S. Jadhav, V. Gulumkar, P. Deshpande, E. T. Coffey, H. Lonnberg and P. Virta, *Bioconjugate Chem.*, 2018, **29**, 2382–2393.
- 11 S. Yang, Q. Liu, G. Y. Zhang, X. X. Zhang, Z. H. Zhao and P. S. Lei, *J. Org. Chem.*, 2018, **83**, 5897–5908.
- 12 J.-C. Jacquinet and C. Lopin-Bon, *Carbohydr. Res.*, 2015, **402**, 35–43.
- 13 J.-i. Tamura, N. Tsutsumishita-Nakai, Y. Nakao, M. Kawano, S. Kato, N. Takeda, S. Nadanaka and H. Kitagawa, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 1371–1374.
- 14 C. Solera, G. Macchione, S. Maza, M. M. Kayser, F. Corzana, J. L. de Paz and P. M. Nieto, *Chem. – Eur. J.*, 2016, **22**, 2356–2369.
- 15 S. Ramadan, T. Li, W. Yang, J. Zhang, Z. Rashidijahanabad, Z. Tan, N. Parameswaran and X. Huang, *ACS Cent. Sci.*, 2020, **6**, 913–920.
- 16 N. S. Gandhi and R. L. Mancera, *Drug Discovery Today*, 2010, **15**, 1058–1069.
- 17 P. Dominguez-Rodriguez, C. Vives, M. Thepaut, F. Fieschi, P. M. Nieto, J. L. de Paz and J. Rojo, *Biomacromolecules*, 2020, **21**, 2726–2734.
- 18 S. Yang, H. Zhang, Q. Liu, S. Sun, P. Lei, Z. Zhao, L. Wu and Y. Wang, *Future Med. Chem.*, 2019, **11**, 1403–1415.
- 19 X. Zhang, W. Yao, X. J. Xu, H. F. Sun, J. H. Zhao, X. B. Meng, M. Y. Wu and Z. J. Li, *Chem. – Eur. J.*, 2018, **24**, 1694–1700.
- 20 S.-G. Lee, J. M. Brown, C. J. Rogers, J. B. Matson, C. Krishnamurthy, M. Rawat and L. C. Hsieh-Wilson, *Chem. Sci.*, 2010, **1**, 322–325.



- 21 C.-J. Yeh, C.-C. Ku, W.-C. Lin, C.-Y. Fan, M. M. L. Zulueta, Y. Manabe, K. Fukase, Y.-K. Li and S.-C. Hung, *ChemBioChem*, 2019, **20**, 237–240.
- 22 J. Revuelta, R. Fuentes, L. Lagartera, M. Jose Hernaiz, A. Bastida, E. Garcia-Junceda and A. Fernandez-Mayoralas, *Chem. Commun.*, 2018, **54**, 13455–13458.
- 23 S. Kohling, J. Blaszkiewicz, G. Ruiz-Gomez, M. I. Fernandez-Bachiller, K. Lemmritzer, N. Panitz, A. G. Beck-Sickinger, J. Schiller, M. T. Pisabarro and J. Rademann, *Chem. Sci.*, 2019, **10**, 866–878.
- 24 K. D. Johnstone, T. Karoli, L. Liu, K. Dredge, E. Copeman, C. P. Li, K. Davis, E. Hammond, I. Bytheway, E. Kostewicz, F. C. K. Chiu, D. M. Shackelford, S. A. Charman, W. N. Charman, J. Harenberg, T. J. Gonda and V. Ferro, *J. Med. Chem.*, 2010, **53**, 1686–1699.
- 25 S. Maza, J. L. de Paz and P. M. Nieto, *Molecules*, 2019, **24**, 1591, DOI: 10.3390/molecules24081591.
- 26 E. Lisztes, E. Mezo, F. Demeter, L. Horvath, S. Bosze, B. I. Toth, A. Borbas and M. Herczeg, *ChemMedChem*, 2021, **16**, 1467–1476.
- 27 T. C. Lim, S. Cai, R. G. Huber, P. J. Bond, P. X. S. Chia, S. L. Khou, S. Gao, S. S. Lee and S.-G. Lee, *Chem. Sci.*, 2018, **9**, 7940–7947.
- 28 R. N. Gangji, N. V. Sankaranarayanan, J. Elste, R. A. Al-Horani, D. K. Afosah, R. Joshi, V. Tiwari and U. R. Desai, *ACS Med. Chem. Lett.*, 2018, **9**, 797–802.
- 29 D. K. Afosah, R. A. Al-Horani, N. V. Sankaranarayanan and U. R. Desai, *J. Med. Chem.*, 2017, **60**, 641–657.
- 30 G. Despras, C. Bernard, A. Perrot, L. Cattiaux, A. Prochiantz, H. Lortat-Jacob and J.-M. Mallet, *Chem. – Eur. J.*, 2013, **19**, 530–539.
- 31 O. P. Dhamale, C. Zong, K. Al-Mafraji and G.-J. Boons, *Org. Biomol. Chem.*, 2014, **12**, 2087–2098.
- 32 D. J. Sheppard, S. A. Cameron, P. C. Tyler and R. Schworer, *Org. Biomol. Chem.*, 2020, **18**, 4728–4733.
- 33 S. Maza, N. Gandia-Aguado, J. L. de Paz and P. M. Nieto, *Bioorg. Med. Chem.*, 2018, **26**, 1076–1085.
- 34 G. Macchione, S. Maza, M. M. Kayser, J. L. de Paz and P. M. Nieto, *Eur. J. Org. Chem.*, 2014, 3868–3884.
- 35 S. Maza, M. Mar Kayser, G. Macchione, J. Lopez-Prados, J. Angulo, J. L. de Paz and P. M. Nieto, *Org. Biomol. Chem.*, 2013, **11**, 3510–3525.
- 36 Q. Zhang, E. R. van Rijssel, M. T. C. Walvoort, H. S. Overkleeft, G. A. van der Marel and J. D. C. Codee, *Angew. Chem., Int. Ed.*, 2015, **54**, 7670–7673.
- 37 H. Lucas, J. E. M. Basten, T. G. Vandinther, D. G. Meuleman, S. F. Vanaelst and C. A. A. Vanboeckel, *Tetrahedron*, 1990, **46**, 8207–8228.
- 38 J. L. de Paz and P. M. Nieto, *Org. Biomol. Chem.*, 2016, **14**, 3506–3509.
- 39 B. Kuhnast, A. El Hadri, R. Boisgard, F. Hinnen, S. Richard, A. Caravano, V. Nancy-Portebois, M. Petitou, B. Tavitian and F. Dolle, *Org. Biomol. Chem.*, 2016, **14**, 1915–1920.
- 40 R. Karuturi, R. A. Al-Horani, S. C. Mehta, D. Gailani and U. R. Desai, *J. Med. Chem.*, 2013, **56**, 2415–2428.
- 41 V. Ferro, L. Liu, K. D. Johnstone, N. Wimmer, T. Karoli, P. Handley, J. Rowley, K. Dredge, C. P. Li, E. Hammond, K. Davis, L. Sarimaa, J. Harenberg and I. Bytheway, *J. Med. Chem.*, 2012, **55**, 3804–3813.
- 42 J. O. Duus, C. H. Gotfredsen and K. Bock, *Chem. Rev.*, 2000, **100**, 4589–4614.
- 43 S. Macura and R. R. Ernst, *Mol. Phys.*, 2002, **100**, 135–147.
- 44 A. E. Torda, R. M. Scheek and W. F. Vangunsteren, *Chem. Phys. Lett.*, 1989, **157**, 289–294.
- 45 B. Meyer and T. Peters, *Angew. Chem., Int. Ed.*, 2003, **42**, 864–890.
- 46 F. Ni, *Prog. Nucl. Magn. Reson. Spectrosc.*, 1994, **26**, 517–606.
- 47 P. M. Nieto, *Front. Mol. Biosci.*, 2018, **5**, 33, DOI: 10.3389/fmolb.2018.00033.
- 48 J. Angulo and P. M. Nieto, *Eur. Biophys. J.*, 2011, **40**, 1357–1369.
- 49 M. Mayer and T. L. James, *J. Am. Chem. Soc.*, 2004, **126**, 4453–4460.
- 50 K. N. Kirschner, A. B. Yongye, S. M. Tschampel, J. Gonzalez-Outeirino, C. R. Daniels, B. L. Foley and R. J. Woods, *J. Comput. Chem.*, 2008, **29**, 622–655.
- 51 F.-Y. Dupradeau, C. Cezard, R. Lelong, E. Stanislawiak, J. Pecher, J. C. Delepine and P. Cieplak, *Nucleic Acids Res.*, 2008, **36**, D360–D367.
- 52 W. L. Jorgensen, J. Chandrasekhar, J. D. Madura, R. W. Impey and M. L. Klein, *J. Chem. Phys.*, 1983, **79**, 926–935.

